{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:08:55Z","timestamp":1794118135323,"version":"4.8.0"},"reference-count":550,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-22-170-01-RMC"],"award-info":[{"award-number":["RSG-22-170-01-RMC"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1R16GM149497"],"award-info":[{"award-number":["1R16GM149497"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-03032-5","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:42:22Z","timestamp":1790239342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RNA therapeutics: current status and future directions"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-1367","authenticated-orcid":false,"given":"Barbara","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7456-666X","authenticated-orcid":false,"given":"Melina J.","family":"Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-7121","authenticated-orcid":false,"given":"Karla","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalakshmi","family":"Vijayaraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-2116","authenticated-orcid":false,"given":"Victoria A.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-8828","authenticated-orcid":false,"given":"Murali M.","family":"Yallapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3347-5120","authenticated-orcid":false,"given":"Subhash C.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4390-3811","authenticated-orcid":false,"given":"Subramanian","family":"Dhandayuthapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-7944","authenticated-orcid":false,"given":"Enrique I.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0030-5472","authenticated-orcid":false,"given":"Shrikanth S.","family":"Gadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"crossref","unstructured":"Casamassimi, A. & Ciccodicola, A. Transcriptional regulation: molecules, involved mechanisms, and misregulation. Int. J. Mol. Sci. 20, 1281 (2019).","DOI":"10.3390\/ijms20061281"},{"key":"3032_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","volume":"136","author":"N Sonenberg","year":"2009","unstructured":"Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731\u2013745 (2009).","journal-title":"Cell"},{"key":"3032_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cell.2009.02.009","volume":"136","author":"MC Wahl","year":"2009","unstructured":"Wahl, M. C., Will, C. L. & Luhrmann, R. The spliceosome: design principles of a dynamic RNP machine. Cell 136, 701\u2013718 (2009).","journal-title":"Cell"},{"key":"3032_CR4","first-page":"9578","volume":"44","author":"M Strenkowska","year":"2016","unstructured":"Strenkowska, M. et al. Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential. Nucleic Acids Res. 44, 9578\u20139590 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","volume":"23","author":"LA Passmore","year":"2022","unstructured":"Passmore, L. A. & Coller, J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat. Rev. Mol. Cell Biol. 23, 93\u2013106 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3032_CR6","doi-asserted-by":"crossref","unstructured":"Min, D. J., Lee, S., Lee, Y. S. & Cho, J. Two codes of RNA editing by deamination in human diseases. Exp. Mol. Med., 58, 382\u2013395 (2026).","DOI":"10.1038\/s12276-025-01633-8"},{"key":"3032_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41576-023-00645-2","volume":"25","author":"S Delaunay","year":"2024","unstructured":"Delaunay, S., Helm, M. & Frye, M. RNA modifications in physiology and disease: towards clinical applications. Nat. Rev. Genet. 25, 104\u2013122 (2024).","journal-title":"Nat. Rev. Genet."},{"key":"3032_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/190576a0","volume":"190","author":"S Brenner","year":"1961","unstructured":"Brenner, S., Jacob, F. & Meselson, M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190, 576\u2013581 (1961).","journal-title":"Nature"},{"key":"3032_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-42059-2_1","volume":"937","author":"S Hombach","year":"2016","unstructured":"Hombach, S. & Kretz, M. Non-coding RNAs: classification, biology and functioning. Adv. Exp. Med. Biol. 937, 3\u201317 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"3032_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509\u2013524 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3032_CR11","doi-asserted-by":"crossref","unstructured":"Chen, C. et al. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer. J Clin. Invest. 131, e146431 (2021).","DOI":"10.1172\/JCI146431"},{"key":"3032_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.116129","volume":"171","author":"M Huang","year":"2026","unstructured":"Huang, M. et al. circSERINC3 facilitates STAT3-CDK5 crosstalk to orchestrate immunosuppressive microenvironments in pancreatic Cancer. Int. Immunopharmacol. 171, 116129 (2026).","journal-title":"Int. Immunopharmacol."},{"key":"3032_CR13","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1038\/sj.onc.1206928","volume":"22","author":"P Ji","year":"2003","unstructured":"Ji, P. et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031\u20138041 (2003).","journal-title":"Oncogene"},{"key":"3032_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01246-x","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. CircRNA inhibits DNA damage repair by interacting with host gene. Mol. Cancer 19, 128 (2020).","journal-title":"Mol. Cancer"},{"key":"3032_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.canlet.2019.11.001","volume":"469","author":"Y Ye","year":"2020","unstructured":"Ye, Y. et al. Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b\/MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma. Cancer Lett. 469, 310\u2013322 (2020).","journal-title":"Cancer Lett."},{"key":"3032_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114916","volume":"159","author":"J Kang","year":"2025","unstructured":"Kang, J. et al. Exosomal miR-574-3p from adipose-derived mesenchymal stem modulates CRIM1\/BMPs signaling to restrain chondrocytes hypertrophy and inflammatory response in knee osteoarthritis. Int. Immunopharmacol. 159, 114916 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"3032_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0620-0","volume":"16","author":"L Liu","year":"2017","unstructured":"Liu, L. et al. MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol. Cancer 16, 50 (2017).","journal-title":"Mol. Cancer"},{"key":"3032_CR18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s11658-023-00447-8","volume":"28","author":"A Safi","year":"2023","unstructured":"Safi, A. et al. The role of noncoding RNAs in metabolic reprogramming of cancer cells. Cell Mol. Biol. Lett. 28, 37 (2023).","journal-title":"Cell Mol. Biol. Lett."},{"key":"3032_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. & Krieg, A. M. FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid Ther. 27, 1\u20133 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1089\/nat.2018.0754","volume":"29","author":"JD Ferrone","year":"2019","unstructured":"Ferrone, J. D. et al. IONIS-PKK(Rx) a novel antisense inhibitor of prekallikrein and bradykinin production. Nucleic Acid Ther. 29, 82\u201391 (2019).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","volume":"26","author":"DS Roseman","year":"2018","unstructured":"Roseman, D. S. et al. G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a. Mol. Ther. 26, 814\u2013821 (2018).","journal-title":"Mol. Ther."},{"key":"3032_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bph.17345","volume":"182","author":"T Szabados","year":"2025","unstructured":"Szabados, T. et al. Pharmacokinetics and cardioprotective efficacy of intravenous miR-125b* microRNA mimic in a mouse model of acute myocardial infarction. Br. J. Pharmcol. 182, 432\u2013450 (2025).","journal-title":"Br. J. Pharmcol."},{"key":"3032_CR23","doi-asserted-by":"crossref","unstructured":"Southey, M. W. Y. & Brunavs, M. Introduction to small molecule drug discovery and preclinical development. Front. Drug Discov. 3, 1314077 (2023).","DOI":"10.3389\/fddsv.2023.1314077"},{"key":"3032_CR24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"3032_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41573-025-01280-8","volume":"25","author":"L Zhang","year":"2026","unstructured":"Zhang, L., Wei, J., Zou, Z. & He, C. RNA modification systems as therapeutic targets. Nat. Rev. Drug Discov. 25, 59\u201378 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR26","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41589-019-0384-5","volume":"15","author":"S Campagne","year":"2019","unstructured":"Campagne, S. et al. Structural basis of a small molecule targeting RNA for a specific splicing correction. Nat. Chem. Biol. 15, 1191\u20131198 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"3032_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova, E. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597\u2013601 (2021).","journal-title":"Nature"},{"key":"3032_CR28","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli, M. & Manoharan, M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51, 2529\u20132573 (2023).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik, P. C. & Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75, 280\u2013284 (1978).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/nar\/7.1.179","volume":"7","author":"H Donis-Keller","year":"1979","unstructured":"Donis-Keller, H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res. 7, 179\u2013192 (1979).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR31","first-page":"670","volume":"26","author":"JM Leeds","year":"1998","unstructured":"Leeds, J. M. et al. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab. Dispos. 26, 670\u2013675 (1998).","journal-title":"Drug Metab. Dispos."},{"key":"3032_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0002-9394(02)01327-2","volume":"133","author":"Vitravene Study Group","year":"2002","unstructured":"Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133, 467\u2013474 (2002).","journal-title":"Am. J. Ophthalmol."},{"key":"3032_CR33","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","volume":"25","author":"XH Liang","year":"2017","unstructured":"Liang, X. H., Sun, H., Nichols, J. G. & Crooke, S. T. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol. Ther. 25, 2075\u20132092 (2017).","journal-title":"Mol. Ther."},{"key":"3032_CR34","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","volume":"4","author":"MC Lauffer","year":"2024","unstructured":"Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A. & Collaborative, N. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun. Med. 4, 6 (2024).","journal-title":"Commun. Med."},{"key":"3032_CR35","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/cvr\/cvae195","volume":"120","author":"M Modder","year":"2024","unstructured":"Modder, M. et al. Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Cardiovasc Res. 120, 2179\u20132190 (2024).","journal-title":"Cardiovasc Res."},{"key":"3032_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101195","volume":"6","author":"M Noguchi","year":"2024","unstructured":"Noguchi, M. et al. Hic-5 antisense oligonucleotide inhibits advanced hepatic fibrosis and steatosis in vivo. JHEP Rep. 6, 101195 (2024).","journal-title":"JHEP Rep."},{"key":"3032_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-024-01766-3","volume":"12","author":"T Sano","year":"2024","unstructured":"Sano, T. et al. Effects of local reduction of endogenous alpha-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice. Acta Neuropathol. Commun. 12, 75 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"3032_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105992","volume":"230","author":"M Yamasaki","year":"2024","unstructured":"Yamasaki, M. et al. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA. Antivir. Res. 230, 105992 (2024).","journal-title":"Antivir. Res."},{"key":"3032_CR39","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen, X. & Corey, D. R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46, 1584\u20131600 (2018).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s43856-024-00712-7","volume":"5","author":"DW Karjosukarso","year":"2025","unstructured":"Karjosukarso, D. W. et al. Preclinical assessment of splicing modulation therapy for ABCA4 variant c.768G>T in Stargardt disease. Commun. Med. 5, 25 (2025).","journal-title":"Commun. Med."},{"key":"3032_CR41","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00018-020-03632-6","volume":"78","author":"A Naveed","year":"2021","unstructured":"Naveed, A. et al. NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma. Cell Mol. Life Sci. 78, 2213\u20132230 (2021).","journal-title":"Cell Mol. Life Sci."},{"key":"3032_CR42","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1093\/nar\/gkae624","volume":"52","author":"D Susorov","year":"2024","unstructured":"Susorov, D., Echeverria, D., Khvorova, A. & Korostelev, A. A. mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs). Nucleic Acids Res. 52, 8687\u20138701 (2024).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR43","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/01.ju.0000134698.87862.e6","volume":"172","author":"YJ Ko","year":"2004","unstructured":"Ko, Y. J. et al. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J. Urol. 172, 1140\u20131144 (2004).","journal-title":"J. Urol."},{"key":"3032_CR44","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1261\/rna.080220.124","volume":"30","author":"AM Vanderplow","year":"2024","unstructured":"Vanderplow, A. M. et al. Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression. RNA 30, 1554\u20131571 (2024).","journal-title":"RNA"},{"key":"3032_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105475","volume":"299","author":"G Aggarwal","year":"2023","unstructured":"Aggarwal, G. et al. Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation. J. Biol. Chem. 299, 105475 (2023).","journal-title":"J. Biol. Chem."},{"key":"3032_CR46","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 90, 8673\u20138677 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR47","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1093\/nar\/gkw533","volume":"44","author":"MA Havens","year":"2016","unstructured":"Havens, M. A. & Hastings, M. L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 44, 6549\u20136563 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR48","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua, Y. et al. Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834\u2013848 (2008).","journal-title":"Am. J. Hum. Genet."},{"key":"3032_CR49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","volume":"18","author":"V Arechavala-Gomeza","year":"2007","unstructured":"Arechavala-Gomeza, V. et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798\u2013810 (2007).","journal-title":"Hum. Gene Ther."},{"key":"3032_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Krutzfeldt","year":"2005","unstructured":"Krutzfeldt, J. et al. Silencing of microRNAs in vivo with \u2018antagomirs. Nature 438, 685\u2013689 (2005).","journal-title":"Nature"},{"key":"3032_CR51","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/apt.13432","volume":"43","author":"MH van der Ree","year":"2016","unstructured":"van der Ree, M. H. et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma. Aliment. Pharmacol. Ther. 43, 102\u2013113 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"3032_CR52","doi-asserted-by":"crossref","unstructured":"Bauersachs, J. et al. The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial. Nat. Med., 32, 2654\u20132661 (2026).","DOI":"10.1038\/s41591-026-04408-4"},{"key":"3032_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65799-5","volume":"16","author":"T Valencia","year":"2025","unstructured":"Valencia, T. et al. The nucleobase guanine at the 3\u2019-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity. Nat. Commun. 16, 10762 (2025).","journal-title":"Nat. Commun."},{"key":"3032_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4015","volume":"384","author":"R Obexer","year":"2024","unstructured":"Obexer, R. et al. Modern approaches to therapeutic oligonucleotide manufacturing. Science 384, eadl4015 (2024).","journal-title":"Science"},{"key":"3032_CR55","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1021\/ja01093a058","volume":"87","author":"RL Letsinger","year":"1965","unstructured":"Letsinger, R. L. & Mahadevan, V. Oligonucleotide synthesis on a polymer support. J. Am. Chem. Soc. 87, 3526\u20133527 (1965).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR56","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1021\/bi00857a021","volume":"6","author":"RL Letsinger","year":"1967","unstructured":"Letsinger, R. L., Caruthers, M. H. & Jerina, D. M. Reactions of nucleosides on polymer supports. Synthesis of thymidylylthymidylylthymidine. Biochemistry 6, 1379\u20131388 (1967).","journal-title":"Biochemistry"},{"key":"3032_CR57","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1021\/ja01040a042","volume":"91","author":"RL Letsinger","year":"1969","unstructured":"Letsinger, R. L. & Ogilvie, K. K. Nucleotide chemistry. XIII. Synthesis of oligothymidylates via phosphotriester intermediates. J. Am. Chem. Soc. 91, 3350\u20133355 (1969).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR58","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1021\/ja00844a090","volume":"97","author":"RI Letsinger","year":"1975","unstructured":"Letsinger, R. I., Finnan, J. L., Heavner, G. A. & Lunsford, N. B. Letter: Phosphite coupling procedure for generating internucleotide links. J. Am. Chem. Soc. 97, 3278\u20133279 (1975).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR59","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0040-4039(01)90461-7","volume":"22","author":"SL Beaucage","year":"1981","unstructured":"Beaucage, S. L. & Caruthers, M. H. Deoxynucleoside phosphoramidites\u2014a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22, 1859\u20131862 (1981).","journal-title":"Tetrahedron Lett."},{"key":"3032_CR60","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s00044-024-03352-7","volume":"33","author":"AA Mohammed","year":"2024","unstructured":"Mohammed, A. A., AlShaer, D. & Al Musaimi, O. Oligonucleotides: evolution and innovation. Med. Chem. Res. 33, 2204\u20132220 (2024).","journal-title":"Med. Chem. Res."},{"key":"3032_CR61","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1021\/ja00332a054","volume":"106","author":"WJ Stec","year":"1984","unstructured":"Stec, W. J., Zon, G. & Egan, W. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106, 6077\u20136079 (1984).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/acs.joc.0c02291","volume":"86","author":"BI Andrews","year":"2021","unstructured":"Andrews, B. I. et al. Sustainability challenges and opportunities in oligonucleotide manufacturing. J. Org. Chem. 86, 49\u201361 (2021).","journal-title":"J. Org. Chem."},{"key":"3032_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52141-8","volume":"15","author":"N Sabat","year":"2024","unstructured":"Sabat, N. et al. Template-dependent DNA ligation for the synthesis of modified oligonucleotides. Nat. Commun. 15, 8009 (2024).","journal-title":"Nat. Commun."},{"key":"3032_CR64","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.add5892","volume":"380","author":"ER Moody","year":"2023","unstructured":"Moody, E. R. et al. An enzyme cascade enables production of therapeutic oligonucleotides in a single operation. Science 380, 1150\u20131154 (2023).","journal-title":"Science"},{"key":"3032_CR65","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.3779","volume":"35","author":"ST Crooke","year":"2017","unstructured":"Crooke, S. T. et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol. 35, 230\u2013237 (2017).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/nat.2022.0067","volume":"33","author":"AJ Pollak","year":"2023","unstructured":"Pollak, A. J., Zhao, L. & Crooke, S. T. Systematic analysis of chemical modifications of phosphorothioate antisense oligonucleotides that modulate their innate immune response. Nucleic Acid Ther. 33, 95\u2013107 (2023).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR67","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"F Eckstein","year":"2014","unstructured":"Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374\u2013387 (2014).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR68","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/nar\/16.8.3209","volume":"16","author":"CA Stein","year":"1988","unstructured":"Stein, C. A., Subasinghe, C., Shinozuka, K. & Cohen, J. S. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209\u20133221 (1988).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR69","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/oli.2006.16.169","volume":"16","author":"TA Watanabe","year":"2006","unstructured":"Watanabe, T. A., Geary, R. S. & Levin, A. A. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169\u2013180 (2006).","journal-title":"Oligonucleotides"},{"key":"3032_CR70","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/nar\/gky1260","volume":"47","author":"HJ Gaus","year":"2019","unstructured":"Gaus, H. J. et al. Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay. Nucleic Acids Res. 47, 1110\u20131122 (2019).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR71","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 44, 6518\u20136548 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR72","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41557-023-01246-6","volume":"15","author":"L Fang","year":"2023","unstructured":"Fang, L. et al. Reversible 2\u2019-OH acylation enhances RNA stability. Nat. Chem. 15, 1296\u20131305 (2023).","journal-title":"Nat. Chem."},{"key":"3032_CR73","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","volume":"38","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases. BioDrugs 38, 177\u2013203 (2024).","journal-title":"BioDrugs"},{"key":"3032_CR74","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/jm00059a007","volume":"36","author":"AM Kawasaki","year":"1993","unstructured":"Kawasaki, A. M. et al. Uniformly modified 2\u2019-deoxy-2\u2019-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36, 831\u2013841 (1993).","journal-title":"J. Med. Chem."},{"key":"3032_CR75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/9304","volume":"6","author":"M Teplova","year":"1999","unstructured":"Teplova, M. et al. Crystal structure and improved antisense properties of 2\u2019-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6, 535\u2013539 (1999).","journal-title":"Nat. Struct. Biol."},{"key":"3032_CR76","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nchembio.939","volume":"8","author":"F Rigo","year":"2012","unstructured":"Rigo, F. et al. Synthetic oligonucleotides recruit ILF2\/3 to RNA transcripts to modulate splicing. Nat. Chem. Biol. 8, 555\u2013561 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"3032_CR77","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1056\/NEJMoa073108","volume":"357","author":"JC van Deutekom","year":"2007","unstructured":"van Deutekom, J. C. et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677\u20132686 (2007).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR78","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hlca.19950780219","volume":"78","author":"P Martin","year":"1995","unstructured":"Martin, P. Ein neuer Zugang zu 2\u2032-O-alkylribonucleosiden und Eigenschaften deren oligonucleotide. Helvetica Chim. Acta 78, 486\u2013504 (1995).","journal-title":"Helvetica Chim. Acta"},{"key":"3032_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/hlca.202200169","volume":"106","author":"AC Hill","year":"2023","unstructured":"Hill, A. C. & Hall, J. The MOE Modification of RNA: origins and widescale impact on the oligonucleotide therapeutics field. Helvetica Chim. Acta 106, e202200169 (2023).","journal-title":"Helvetica Chim. Acta"},{"key":"3032_CR80","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/nat.2020.0917","volume":"31","author":"W Partridge","year":"2021","unstructured":"Partridge, W. et al. Improvements in the tolerability profile of 2\u2019-O-methoxyethyl chimeric antisense oligonucleotides in parallel with advances in design, screening, and other methods. Nucleic Acid Ther. 31, 417\u2013426 (2021).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/nat.2016.0650","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke, S. T. et al. The effects of 2\u2019-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther. 27, 121\u2013129 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR82","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/mt.2016.136","volume":"24","author":"ST Crooke","year":"2016","unstructured":"Crooke, S. T. et al. Integrated safety assessment of 2\u2019-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol. Ther. 24, 1771\u20131782 (2016).","journal-title":"Mol. Ther."},{"key":"3032_CR83","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.1016\/S0040-4039(97)10322-7","volume":"38","author":"S Obika","year":"1997","unstructured":"Obika, S. et al. Synthesis of 2\u2032-O,4\u2032-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3, -endo sugar puckering. Tetrahedron Lett. 38, 8735\u20138738 (1997).","journal-title":"Tetrahedron Lett."},{"key":"3032_CR84","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1016\/S0040-4039(98)01084-3","volume":"39","author":"S Obika","year":"1998","unstructured":"Obika, S. et al. Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2\u2032-O,4\u2032-C-methyleneribonucleosides. Tetrahedron Lett. 39, 5401\u20135404 (1998).","journal-title":"Tetrahedron Lett."},{"key":"3032_CR85","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.786","volume":"43","author":"S Obad","year":"2011","unstructured":"Obad, S. et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43, 371\u2013378 (2011).","journal-title":"Nat. Genet."},{"key":"3032_CR86","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1093\/nar\/gkac630","volume":"50","author":"M Shin","year":"2022","unstructured":"Shin, M. et al. Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts. Nucleic Acids Res. 50, 8418\u20138430 (2022).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drudis.2017.09.018","volume":"23","author":"PH Hagedorn","year":"2018","unstructured":"Hagedorn, P. H. et al. Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov. Today 23, 101\u2013114 (2018).","journal-title":"Drug Discov. Today"},{"key":"3032_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/jm801294h","volume":"52","author":"PP Seth","year":"2009","unstructured":"Seth, P. P. et al. Short antisense oligonucleotides with novel 2\u2019-4\u2019 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10\u201313 (2009).","journal-title":"J. Med. Chem."},{"key":"3032_CR89","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 13, 2394\u20132411 (2023).","journal-title":"Cancer Discov."},{"key":"3032_CR90","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","volume":"268","author":"BP Monia","year":"1993","unstructured":"Monia, B. P. et al. Evaluation of 2\u2019-modified oligonucleotides containing 2\u2019-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514\u201314522 (1993).","journal-title":"J. Biol. Chem."},{"key":"3032_CR91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-024-00725-9","volume":"19","author":"L Vandermeulen","year":"2024","unstructured":"Vandermeulen, L. et al. Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer\u2019s disease. Mol. Neurodegener. 19, 37 (2024).","journal-title":"Mol. Neurodegener."},{"key":"3032_CR92","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","volume":"27","author":"MF Yuen","year":"2021","unstructured":"Yuen, M. F. et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat. Med. 27, 1725\u20131734 (2021).","journal-title":"Nat. Med."},{"key":"3032_CR93","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","volume":"394","author":"J Hou","year":"2026","unstructured":"Hou, J. et al. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N. Engl. J. Med. 394, 2395\u20132406 (2026).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR94","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1093\/nar\/17.15.6129","volume":"17","author":"EP Stirchak","year":"1989","unstructured":"Stirchak, E. P., Summerton, J. E. & Weller, D. D. Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res. 17, 6129\u20136141 (1989).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59494-8","volume":"16","author":"MNA Shah","year":"2025","unstructured":"Shah, M. N. A. et al. DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function. Nat. Commun. 16, 4477 (2025).","journal-title":"Nat. Commun."},{"key":"3032_CR96","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","volume":"6","author":"RM Hudziak","year":"1996","unstructured":"Hudziak, R. M. et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267\u2013272 (1996).","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"3032_CR97","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton, J. & Weller, D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187\u2013195 (1997).","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"3032_CR98","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/mt.2013.263","volume":"22","author":"SN Pandey","year":"2014","unstructured":"Pandey, S. N., Lee, Y. C., Yokota, T. & Chen, Y. W. Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice. Mol. Ther. 22, 390\u2013396 (2014).","journal-title":"Mol. Ther."},{"key":"3032_CR99","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed, Y. Y. Eteplirsen: first global approval. Drugs 76, 1699\u20131704 (2016).","journal-title":"Drugs"},{"key":"3032_CR100","doi-asserted-by":"publisher","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","volume":"59","author":"WB Wan","year":"2016","unstructured":"Wan, W. B. & Seth, P. P. The medicinal chemistry of therapeutic oligonucleotides. J. Med. Chem. 59, 9645\u20139667 (2016).","journal-title":"J. Med. Chem."},{"key":"3032_CR101","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1021\/jm900730r","volume":"52","author":"D Yu","year":"2009","unstructured":"Yu, D. et al. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J. Med. Chem. 52, 5108\u20135114 (2009).","journal-title":"J. Med. Chem."},{"key":"3032_CR102","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Kariko","year":"2005","unstructured":"Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"3032_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","volume":"73","author":"P Hair","year":"2013","unstructured":"Hair, P., Cameron, F. & McKeage, K. Mipomersen sodium: first global approval. Drugs 73, 487\u2013493 (2013).","journal-title":"Drugs"},{"key":"3032_CR104","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/j.1742-4658.2007.05712.x","volume":"274","author":"X Hou","year":"2007","unstructured":"Hou, X., Aguilar, M. I. & Small, D. H. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 274, 1637\u20131650 (2007).","journal-title":"FEBS J."},{"key":"3032_CR105","doi-asserted-by":"crossref","unstructured":"Al Shaer, D., Al Musaimi, O., Albericio, F. & de la Torre, B. G. 2018 FDA tides harvest. Pharmaceuticals 12, 52 (2019).","DOI":"10.3390\/ph12020052"},{"key":"3032_CR106","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie, T. Eplontersen: first approval. Drugs 84, 473\u2013478 (2024).","journal-title":"Drugs"},{"key":"3032_CR107","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair, H. A. Tofersen: first approval. Drugs 83, 1039\u20131043 (2023).","journal-title":"Drugs"},{"key":"3032_CR108","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar, M. et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19, 1248\u20131258 (2022).","journal-title":"Neurotherapeutics"},{"key":"3032_CR109","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa2512761","volume":"394","author":"NA Marston","year":"2026","unstructured":"Marston, N. A. et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. N. Engl. J. Med. 394, 429\u2013441 (2026).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR110","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40265-025-02166-0","volume":"85","author":"YY Syed","year":"2025","unstructured":"Syed, Y. Y. Olezarsen: first approval. Drugs 85, 571\u2013576 (2025).","journal-title":"Drugs"},{"key":"3032_CR111","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.tips.2025.05.007","volume":"46","author":"J Jin","year":"2025","unstructured":"Jin, J. et al. The ASO drug olezarsen targets familial chylomicronemia syndrome. Trends Pharmacol. Sci. 46, 814\u2013815 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"3032_CR112","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-025-02257-y","volume":"86","author":"YY Syed","year":"2026","unstructured":"Syed, Y. Y. Donidalorsen: first approval. Drugs 86, 243\u2013248 (2026).","journal-title":"Drugs"},{"key":"3032_CR113","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl, M. A. et al. Efficacy and safety of donidalorsen for hereditary angioedema. N. Engl. J. Med. 391, 21\u201331 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR114","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo, Y. A. Golodirsen: first approval. Drugs 80, 329\u2013333 (2020).","journal-title":"Drugs"},{"key":"3032_CR115","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Viltolarsen: first approval. Drugs 80, 1027\u20131031 (2020).","journal-title":"Drugs"},{"key":"3032_CR116","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley, M. Casimersen: first approval. Drugs 81, 875\u2013879 (2021).","journal-title":"Drugs"},{"key":"3032_CR117","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy, S. M. Nusinersen: first global approval. Drugs 77, 473\u2013479 (2017).","journal-title":"Drugs"},{"key":"3032_CR118","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR119","first-page":"3931","volume":"63","author":"A Asai","year":"2003","unstructured":"Asai, A. et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63, 3931\u20133939 (2003).","journal-title":"Cancer Res."},{"key":"3032_CR120","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70076","volume":"17","author":"AL Lennox","year":"2024","unstructured":"Lennox, A. L. et al. Imetelstat, a novel, first-in-class telomerase inhibitor: mechanism of action, clinical, and translational science. Clin. Transl. Sci. 17, e70076 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"3032_CR121","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2307\/3869076","volume":"2","author":"C Napoli","year":"1990","unstructured":"Napoli, C., Lemieux, C. & Jorgensen, R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2, 279\u2013289 (1990).","journal-title":"Plant Cell"},{"key":"3032_CR122","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806\u2013811 (1998).","journal-title":"Nature"},{"key":"3032_CR123","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","volume":"75","author":"RC Lee","year":"1993","unstructured":"Lee, R. C., Feinbaum, R. L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843\u2013854 (1993).","journal-title":"Cell"},{"key":"3032_CR124","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/0092-8674(93)90530-4","volume":"75","author":"B Wightman","year":"1993","unstructured":"Wightman, B., Ha, I. & Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75, 855\u2013862 (1993).","journal-title":"Cell"},{"key":"3032_CR125","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1062961","volume":"293","author":"G Hutvagner","year":"2001","unstructured":"Hutvagner, G. et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293, 834\u2013838 (2001).","journal-title":"Science"},{"key":"3032_CR126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nm828","volume":"9","author":"E Song","year":"2003","unstructured":"Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347\u2013351 (2003).","journal-title":"Nat. Med."},{"key":"3032_CR127","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067\u20131070 (2010).","journal-title":"Nature"},{"key":"3032_CR128","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","volume":"383","author":"K Fitzgerald","year":"2014","unstructured":"Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383, 60\u201368 (2014).","journal-title":"Lancet"},{"key":"3032_CR129","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 122, 1630\u20131637 (2020).","journal-title":"Br. J. Cancer"},{"key":"3032_CR130","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy, S. M. Patisiran: first global approval. Drugs 78, 1625\u20131631 (2018).","journal-title":"Drugs"},{"key":"3032_CR131","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","volume":"23","author":"Y Lee","year":"2004","unstructured":"Lee, Y. et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051\u20134060 (2004).","journal-title":"EMBO J."},{"key":"3032_CR132","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature03120","volume":"432","author":"RI Gregory","year":"2004","unstructured":"Gregory, R. I. et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 432, 235\u2013240 (2004).","journal-title":"Nature"},{"key":"3032_CR133","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1126\/science.1178705","volume":"326","author":"C Okada","year":"2009","unstructured":"Okada, C. et al. A high-resolution structure of the pre-microRNA nuclear export machinery. Science 326, 1275\u20131279 (2009).","journal-title":"Science"},{"key":"3032_CR134","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1101\/gad.1424106","volume":"20","author":"I Behm-Ansmant","year":"2006","unstructured":"Behm-Ansmant, I. et al. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 20, 1885\u20131898 (2006).","journal-title":"Genes Dev."},{"key":"3032_CR135","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1073\/pnas.0510928103","volume":"103","author":"L Wu","year":"2006","unstructured":"Wu, L., Fan, J. & Belasco, J. G. MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. USA 103, 4034\u20134039 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR136","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature03315","volume":"433","author":"LP Lim","year":"2005","unstructured":"Lim, L. P. et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433, 769\u2013773 (2005).","journal-title":"Nature"},{"key":"3032_CR137","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrg2936","volume":"12","author":"E Huntzinger","year":"2011","unstructured":"Huntzinger, E. & Izaurralde, E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 12, 99\u2013110 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"3032_CR138","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","volume":"70","author":"AG Bader","year":"2010","unstructured":"Bader, A. G., Brown, D. & Winkler, M. The promise of microRNA replacement therapy. Cancer Res. 70, 7027\u20137030 (2010).","journal-title":"Cancer Res."},{"key":"3032_CR139","doi-asserted-by":"publisher","first-page":"708765","DOI":"10.3389\/fonc.2021.708765","volume":"11","author":"K Otmani","year":"2021","unstructured":"Otmani, K. & Lewalle, P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front. Oncol. 11, 708765 (2021).","journal-title":"Front. Oncol."},{"key":"3032_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2016.12.003","volume":"182","author":"A Yu","year":"2017","unstructured":"Yu, A. et al. MiR-124 contributes to M2 polarization of microglia and confers brain inflammatory protection via the C\/EBP-alpha pathway in intracerebral hemorrhage. Immunol. Lett. 182, 1\u201311 (2017).","journal-title":"Immunol. Lett."},{"key":"3032_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123589","volume":"325","author":"Z Ma","year":"2025","unstructured":"Ma, Z. et al. Lipid nanoparticle-mediated delivery of microRNA-124 reduces neuroinflammation. Biomaterials 325, 123589 (2025).","journal-title":"Biomaterials"},{"key":"3032_CR142","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","volume":"15","author":"JF Lima","year":"2018","unstructured":"Lima, J. F. et al. Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol. 15, 338\u2013352 (2018).","journal-title":"RNA Biol."},{"key":"3032_CR143","doi-asserted-by":"publisher","first-page":"40226","DOI":"10.1021\/acsami.5c07950","volume":"17","author":"C Miao","year":"2025","unstructured":"Miao, C. et al. M1 macrophage-derived extracellular vesicles loaded with CX3CR1 siRNA for the treatment of pancreatic cancer. ACS Appl. Mater. Interfaces 17, 40226\u201340236 (2025).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"3032_CR144","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam, S. J. Vutrisiran: first approval. Drugs 82, 1419\u20131425 (2022).","journal-title":"Drugs"},{"key":"3032_CR145","doi-asserted-by":"crossref","unstructured":"Hu, J. et al. Modulation of TTR gene expression in the eye using modified siRNAs. Nucleic Acids Res. 53, gkaf409 (2025).","DOI":"10.1093\/nar\/gkaf409"},{"key":"3032_CR146","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","volume":"73","author":"E Uijl","year":"2019","unstructured":"Uijl, E. et al. Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen. Hypertension 73, 1249\u20131257 (2019).","journal-title":"Hypertension"},{"key":"3032_CR147","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai, A. S. et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N. Engl. J. Med. 389, 228\u2013238 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR148","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1101\/gad.862301","volume":"15","author":"SM Elbashir","year":"2001","unstructured":"Elbashir, S. M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188\u2013200 (2001).","journal-title":"Genes Dev."},{"key":"3032_CR149","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt1051","volume":"23","author":"DH Kim","year":"2005","unstructured":"Kim, D. H. et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222\u2013226 (2005).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR150","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1111\/j.1742-4658.2010.07903.x","volume":"277","author":"SP Walton","year":"2010","unstructured":"Walton, S. P., Wu, M., Gredell, J. A. & Chan, C. Designing highly active siRNAs for therapeutic applications. FEBS J. 277, 4806\u20134813 (2010).","journal-title":"FEBS J."},{"key":"3032_CR151","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(03)00801-8","volume":"115","author":"A Khvorova","year":"2003","unstructured":"Khvorova, A., Reynolds, A. & Jayasena, S. D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209\u2013216 (2003).","journal-title":"Cell"},{"key":"3032_CR152","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nsmb886","volume":"12","author":"GB Robb","year":"2005","unstructured":"Robb, G. B., Brown, K. M., Khurana, J. & Rana, T. M. Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol. 12, 133\u2013137 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"3032_CR153","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.celrep.2013.12.013","volume":"6","author":"KT Gagnon","year":"2014","unstructured":"Gagnon, K. T. et al. RNAi factors are present and active in human cell nuclei. Cell Rep. 6, 211\u2013221 (2014).","journal-title":"Cell Rep."},{"key":"3032_CR154","doi-asserted-by":"publisher","first-page":"E5756","DOI":"10.1073\/pnas.1721346115","volume":"115","author":"D Castanotto","year":"2018","unstructured":"Castanotto, D. et al. A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. Proc. Natl. Acad. Sci. USA. 115, E5756\u2013E5765 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR155","doi-asserted-by":"crossref","unstructured":"Hofman, C. R. et al. Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression. Nucleic Acids Res. 53, gkaf800 (2025).","DOI":"10.1093\/nar\/gkaf800"},{"key":"3032_CR156","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1261\/rna.079500.122","volume":"29","author":"KC Johnson","year":"2023","unstructured":"Johnson, K. C. & Corey, D. R. RNAi in cell nuclei: potential for a new layer of biological regulation and a new strategy for therapeutic discovery. RNA 29, 415\u2013422 (2023).","journal-title":"RNA"},{"key":"3032_CR157","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.addr.2010.03.008","volume":"62","author":"P Guo","year":"2010","unstructured":"Guo, P. et al. Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug Deliv. Rev. 62, 650\u2013666 (2010).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR158","first-page":"141","volume":"629","author":"CB Moore","year":"2010","unstructured":"Moore, C. B., Guthrie, E. H., Huang, M. T. & Taxman, D. J. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol. Biol. 629, 141\u2013158 (2010).","journal-title":"Methods Mol. Biol."},{"key":"3032_CR159","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1007\/s11095-011-0608-1","volume":"28","author":"S Singh","year":"2011","unstructured":"Singh, S., Narang, A. S. & Mahato, R. I. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 28, 2996\u20133015 (2011).","journal-title":"Pharm. Res."},{"key":"3032_CR160","doi-asserted-by":"publisher","first-page":"e70163","DOI":"10.1002\/cpz1.70163","volume":"5","author":"TN Sata","year":"2025","unstructured":"Sata, T. N., Ismail, M., Sah, A. K. & Venugopal, S. K. Production of functional miRNA mimics using in vitro transcription. Curr. Protoc. 5, e70163 (2025).","journal-title":"Curr. Protoc."},{"key":"3032_CR161","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1002\/anie.201006519","volume":"50","author":"M Manoharan","year":"2011","unstructured":"Manoharan, M. et al. Unique gene-silencing and structural properties of 2\u2019-fluoro-modified siRNAs. Angew. Chem. Int. Ed. Engl. 50, 2284\u20132288 (2011).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"3032_CR162","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3762\/bjoc.17.76","volume":"17","author":"C Liczner","year":"2021","unstructured":"Liczner, C. et al. Beyond ribose and phosphate: selected nucleic acid modifications for structure-function investigations and therapeutic applications. Beilstein J. Org. Chem. 17, 908\u2013931 (2021).","journal-title":"Beilstein J. Org. Chem."},{"key":"3032_CR163","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cell.2012.05.017","volume":"150","author":"E Elkayam","year":"2012","unstructured":"Elkayam, E. et al. The structure of human argonaute-2 in complex with miR-20a. Cell 150, 100\u2013110 (2012).","journal-title":"Cell"},{"key":"3032_CR164","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1093\/nar\/gkw1171","volume":"45","author":"E Elkayam","year":"2017","unstructured":"Elkayam, E. et al. siRNA carrying an (E)-vinylphosphonate moiety at the 5\u0384 end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res. 45, 3528\u20133536 (2017).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR165","doi-asserted-by":"publisher","first-page":"13024","DOI":"10.1039\/D4CC04302B","volume":"60","author":"D Datta","year":"2024","unstructured":"Datta, D. et al. Conformation matters: siRNAs with antisense strands with 5\u2019-(E)-vinyl-phosphonate-alpha-L-LNA elicit stronger RNAi-mediated gene silencing than those with 5\u2019-(E)-vinyl-phosphonate-LNA. Chem. Commun. 60, 13024\u201313027 (2024).","journal-title":"Chem. Commun."},{"key":"3032_CR166","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1039\/C9CC00977A","volume":"55","author":"P Kumar","year":"2019","unstructured":"Kumar, P. et al. 5\u2019-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger. Chem. Commun. 55, 5139\u20135142 (2019).","journal-title":"Chem. Commun."},{"key":"3032_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10154","volume":"6","author":"HS Lee","year":"2015","unstructured":"Lee, H. S. et al. Abasic pivot substitution harnesses target specificity of RNA interference. Nat. Commun. 6, 10154 (2015).","journal-title":"Nat. Commun."},{"key":"3032_CR168","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1093\/nar\/gkac539","volume":"50","author":"MK Schlegel","year":"2022","unstructured":"Schlegel, M. K. et al. From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization. Nucleic Acids Res. 50, 6656\u20136670 (2022).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR169","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"I Urits","year":"2020","unstructured":"Urits, I. et al. A review of patisiran (ONPATTRO(R)) for the Treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol. Ther. 9, 301\u2013315 (2020).","journal-title":"Neurol. Ther."},{"key":"3032_CR170","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/17460441.2024.2306843","volume":"19","author":"V Plante-Bordeneuve","year":"2024","unstructured":"Plante-Bordeneuve, V. & Perrain, V. Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy. Expert Opin. Drug Discov. 19, 393\u2013402 (2024).","journal-title":"Expert Opin. Drug Discov."},{"key":"3032_CR171","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J. Med. 392, 33\u201344 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR172","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott, L. J. Givosiran: first approval. Drugs 80, 335\u2013339 (2020).","journal-title":"Drugs"},{"key":"3032_CR173","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/mt.2015.224","volume":"24","author":"C Martin-Higueras","year":"2016","unstructured":"Martin-Higueras, C., Luis-Lima, S. & Salido, E. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I. Mol. Ther. 24, 719\u2013725 (2016).","journal-title":"Mol. Ther."},{"key":"3032_CR174","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs, S. F. et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N. Engl. J. Med. 384, 1216\u20131226 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR175","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","volume":"81","author":"LJ Scott","year":"2021","unstructured":"Scott, L. J. & Keam, S. J. Lumasiran: first approval. Drugs 81, 277\u2013282 (2021).","journal-title":"Drugs"},{"key":"3032_CR176","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","volume":"83","author":"YY Syed","year":"2023","unstructured":"Syed, Y. Y. Nedosiran: first approval. Drugs 83, 1729\u20131733 (2023).","journal-title":"Drugs"},{"key":"3032_CR177","doi-asserted-by":"crossref","unstructured":"Revaiah, P. C. et al. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - the VICTORION-PLAQUE primary prevention trial. Am. Heart J., 291, 199\u2013212 (2025).","DOI":"10.1016\/j.ahj.2025.08.001"},{"key":"3032_CR178","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb, Y. N. Inclisiran: first approval. Drugs 81, 389\u2013395 (2021).","journal-title":"Drugs"},{"key":"3032_CR179","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/JBM.S390521","volume":"14","author":"S Boyce","year":"2023","unstructured":"Boyce, S. & Rangarajan, S. RNAi for the treatment of people with hemophilia: current evidence and patient selection. J. Blood Med. 14, 317\u2013327 (2023).","journal-title":"J. Blood Med."},{"key":"3032_CR180","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s40265-025-02203-y","volume":"85","author":"A Lee","year":"2025","unstructured":"Lee, A. Fitusiran: first approval. Drugs 85, 1073\u20131077 (2025).","journal-title":"Drugs"},{"key":"3032_CR181","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne, C. M. et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N. Engl. J. Med. 391, 899\u2013912 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR182","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","volume":"346","author":"AD Ellington","year":"1990","unstructured":"Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818\u2013822 (1990).","journal-title":"Nature"},{"key":"3032_CR183","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"C Tuerk","year":"1990","unstructured":"Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505\u2013510 (1990).","journal-title":"Science"},{"key":"3032_CR184","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","volume":"9","author":"AD Keefe","year":"2010","unstructured":"Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537\u2013550 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR185","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/355564a0","volume":"355","author":"LC Bock","year":"1992","unstructured":"Bock, L. C. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564\u2013566 (1992).","journal-title":"Nature"},{"key":"3032_CR186","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI11325","volume":"106","author":"RR White","year":"2000","unstructured":"White, R. R., Sullenger, B. A. & Rusconi, C. P. Developing aptamers into therapeutics. J. Clin. Invest. 106, 929\u2013934 (2000).","journal-title":"J. Clin. Invest."},{"key":"3032_CR187","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1182\/blood.V81.12.3271.3271","volume":"81","author":"LC Griffin","year":"1993","unstructured":"Griffin, L. C. et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81, 3271\u20133276 (1993).","journal-title":"Blood"},{"key":"3032_CR188","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1681\/ASN.2006121348","volume":"18","author":"O Kulkarni","year":"2007","unstructured":"Kulkarni, O. et al. Spiegelmer inhibition of CCL2\/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J. Am. Soc. Nephrol. 18, 2350\u20132358 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3032_CR189","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.virol.2008.08.025","volume":"381","author":"C Cohen","year":"2008","unstructured":"Cohen, C. et al. An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 381, 46\u201354 (2008).","journal-title":"Virology"},{"key":"3032_CR190","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1006\/bbrc.2002.6354","volume":"290","author":"F Ylera","year":"2002","unstructured":"Ylera, F., Lurz, R., Erdmann, V. A. & Furste, J. P. Selection of RNA aptamers to the Alzheimer\u2019s disease amyloid peptide. Biochem. Biophys. Res. Commun. 290, 1583\u20131588 (2002).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3032_CR191","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas, E. S. et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805\u20132816 (2004).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR192","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/d41573-023-00148-z","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard, A. FDA approves second RNA aptamer. Nat. Rev. Drug Discov. 22, 774 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR193","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nrd.2017.86","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou, J. & Rossi, J. Aptamers as targeted therapeutics: current potential and challenges. Nat. Rev. Drug Discov. 16, 440 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR194","doi-asserted-by":"crossref","unstructured":"Sequeira-Antunes, B. & Ferreira, H. A. Nucleic acid aptamer-based biosensors: a review. Biomedicines 11, 3201 (2023).","DOI":"10.3390\/biomedicines11123201"},{"key":"3032_CR195","doi-asserted-by":"publisher","first-page":"103550","DOI":"10.1016\/j.drudis.2023.103550","volume":"28","author":"D Sanjanwala","year":"2023","unstructured":"Sanjanwala, D. & Patravale, V. Aptamers and nanobodies as alternatives to antibodies for ligand-targeted drug delivery in cancer. Drug Discov. Today 28, 103550 (2023).","journal-title":"Drug Discov. Today"},{"key":"3032_CR196","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401136121","volume":"121","author":"VN Kolyadko","year":"2024","unstructured":"Kolyadko, V. N. et al. An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXa. Proc. Natl. Acad. Sci. USA. 121, e2401136121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR197","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s12276-022-00760-w","volume":"54","author":"NO Yunn","year":"2022","unstructured":"Yunn, N. O. et al. An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration. Exp. Mol. Med. 54, 531\u2013541 (2022).","journal-title":"Exp. Mol. Med."},{"key":"3032_CR198","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1021\/acs.jcim.5c00295","volume":"65","author":"I Diakogiannaki","year":"2025","unstructured":"Diakogiannaki, I. et al. Targeting glioblastoma stem cells via EphA2: structural insights into the RNA aptamer A40s for precision therapy. J. Chem. Inf. Model 65, 5635\u20135648 (2025).","journal-title":"J. Chem. Inf. Model"},{"key":"3032_CR199","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202300374","volume":"19","author":"R Mahmoud","year":"2024","unstructured":"Mahmoud, R. et al. Aptabinding of tumor necrosis factor-alpha (TNFalpha) inhibits its proinflammatory effects and alleviates islet inflammation. Biotechnol. J. 19, e2300374 (2024).","journal-title":"Biotechnol. J."},{"key":"3032_CR200","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1111\/bph.16399","volume":"181","author":"B Fernandez-Gomez","year":"2024","unstructured":"Fernandez-Gomez, B. et al. ApTOLL: a new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis. Br. J. Pharmacol. 181, 3263\u20133281 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"3032_CR201","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/0008-5472.CAN-24-4039","volume":"85","author":"CD Cruz-Hernandez","year":"2025","unstructured":"Cruz-Hernandez, C. D. et al. A cyanobacteria-derived RNA aptamer resensitizes prostate cancer to hormone therapy. Cancer Res. 85, 2714\u20132725 (2025).","journal-title":"Cancer Res."},{"key":"3032_CR202","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaneurol.2023.1660","volume":"80","author":"M Hernandez-Jimenez","year":"2023","unstructured":"Hernandez-Jimenez, M. et al. Safety and efficacy of ApTOLL in patients with ischemic stroke undergoing endovascular treatment: a phase 1\/2 randomized clinical trial. JAMA Neurol. 80, 779\u2013788 (2023).","journal-title":"JAMA Neurol."},{"key":"3032_CR203","doi-asserted-by":"publisher","first-page":"10361","DOI":"10.1002\/ange.202100345","volume":"133","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Neutralizing aptamers block S\/RBD-ACE2 interactions and prevent host cell infection. Angew. Chem. Weinh. Bergstr. Ger. 133, 10361\u201310366 (2021).","journal-title":"Angew. Chem. Weinh. Bergstr. Ger."},{"key":"3032_CR204","doi-asserted-by":"crossref","unstructured":"Xu, L. et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc. Natl. Acad. Sci. USA. 118, e2012748118 (2021).","DOI":"10.1073\/pnas.2012748118"},{"key":"3032_CR205","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbrc.2007.04.007","volume":"357","author":"F Chen","year":"2007","unstructured":"Chen, F. et al. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. 357, 743\u2013748 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3032_CR206","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.chembiol.2015.01.005","volume":"22","author":"J Zhou","year":"2015","unstructured":"Zhou, J. et al. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem. Biol. 22, 379\u2013390 (2015).","journal-title":"Chem. Biol."},{"key":"3032_CR207","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2514681123","volume":"123","author":"W Cui","year":"2026","unstructured":"Cui, W. et al. Identifying a cancer therapeutic target: Cell-SELEX identifies a membrane protein for aptamer-mediated growth suppression. Proc. Natl. Acad. Sci. USA. 123, e2514681123 (2026).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR208","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nchembio.277","volume":"6","author":"J Mi","year":"2010","unstructured":"Mi, J. et al. In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 6, 22\u201324 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"3032_CR209","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/IJN.S188003","volume":"14","author":"L Chen","year":"2019","unstructured":"Chen, L. et al. In vivo SELEX of bone targeting aptamer in prostate cancer bone metastasis model. Int. J. Nanomed. 14, 149\u2013159 (2019).","journal-title":"Int. J. Nanomed."},{"key":"3032_CR210","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7150\/thno.99588","volume":"15","author":"X Fu","year":"2025","unstructured":"Fu, X. et al. Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma. Theranostics 15, 103\u2013121 (2025).","journal-title":"Theranostics"},{"key":"3032_CR211","doi-asserted-by":"publisher","first-page":"21129","DOI":"10.1021\/acsnano.2c09093","volume":"16","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Bispecific aptamer-based recognition-then-conjugation strategy for PD1\/PDL1 axis blockade and enhanced immunotherapy. ACS Nano 16, 21129\u201321138 (2022).","journal-title":"ACS Nano"},{"key":"3032_CR212","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41589-025-01868-6","volume":"21","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Single-step discovery of high-affinity RNA ligands by UltraSelex. Nat. Chem. Biol. 21, 1118\u20131126 (2025).","journal-title":"Nat. Chem. Biol."},{"key":"3032_CR213","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.febslet.2007.04.072","volume":"581","author":"J Kang","year":"2007","unstructured":"Kang, J., Lee, M. S., Watowich, S. J. & Gorenstein, D. G. Combinatorial selection of a RNA thioaptamer that binds to Venezuelan equine encephalitis virus capsid protein. FEBS Lett. 581, 2497\u20132502 (2007).","journal-title":"FEBS Lett."},{"key":"3032_CR214","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1021\/jacs.9b00104","volume":"141","author":"M Egli","year":"2019","unstructured":"Egli, M. & Lybrand, T. P. Enhanced dispersion and polarization interactions achieved through dithiophosphate group incorporation yield a dramatic binding affinity increase for an RNA aptamer-thrombin complex. J. Am. Chem. Soc. 141, 4445\u20134452 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR215","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/nat.2017.0680","volume":"27","author":"C Kratschmer","year":"2017","unstructured":"Kratschmer, C. & Levy, M. Effect of chemical modifications on aptamer stability in serum. Nucleic Acid Ther. 27, 335\u2013344 (2017).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR216","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1093\/nar\/22.24.5229","volume":"22","author":"Y Lin","year":"1994","unstructured":"Lin, Y., Qiu, Q., Gill, S. C. & Jayasena, S. D. Modified RNA sequence pools for in vitro selection. Nucleic Acids Res. 22, 5229\u20135234 (1994).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR217","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1093\/nar\/gks294","volume":"40","author":"KW Thiel","year":"2012","unstructured":"Thiel, K. W. et al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 40, 6319\u20136337 (2012).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR218","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2022016571","volume":"141","author":"C Ay","year":"2023","unstructured":"Ay, C. et al. The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A. Blood 141, 1147\u20131158 (2023).","journal-title":"Blood"},{"key":"3032_CR219","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nbt0996-1116","volume":"14","author":"A Nolte","year":"1996","unstructured":"Nolte, A. et al. Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat. Biotechnol. 14, 1116\u20131119 (1996).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR220","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s41587-022-01337-8","volume":"40","author":"J Chen","year":"2022","unstructured":"Chen, J., Chen, M. & Zhu, T. F. Directed evolution and selection of biostable L-DNA aptamers with a mirror-image DNA polymerase. Nat. Biotechnol. 40, 1601\u20131609 (2022).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR221","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48416-9","volume":"15","author":"FA Giordano","year":"2024","unstructured":"Giordano, F. A. et al. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial. Nat. Commun. 15, 4210 (2024).","journal-title":"Nat. Commun."},{"key":"3032_CR222","doi-asserted-by":"publisher","first-page":"8706","DOI":"10.1074\/jbc.M113.532580","volume":"289","author":"S Gupta","year":"2014","unstructured":"Gupta, S. et al. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. J. Biol. Chem. 289, 8706\u20138719 (2014).","journal-title":"J. Biol. Chem."},{"key":"3032_CR223","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1093\/nar\/gkh862","volume":"32","author":"KS Schmidt","year":"2004","unstructured":"Schmidt, K. S. et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. 32, 5757\u20135765 (2004).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR224","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/bc0256547","volume":"14","author":"T Schoetzau","year":"2003","unstructured":"Schoetzau, T. et al. Aminomodified nucleobases: functionalized nucleoside triphosphates applicable for SELEX. Bioconjug Chem. 14, 919\u2013926 (2003).","journal-title":"Bioconjug Chem."},{"key":"3032_CR225","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2556","volume":"31","author":"M Kimoto","year":"2013","unstructured":"Kimoto, M. et al. Generation of high-affinity DNA aptamers using an expanded genetic alphabet. Nat. Biotechnol. 31, 453\u2013457 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR226","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1021\/ja908035g","volume":"132","author":"JD Vaught","year":"2010","unstructured":"Vaught, J. D. et al. Expanding the chemistry of DNA for in vitro selection. J. Am. Chem. Soc. 132, 4141\u20134151 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR227","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/oli.2005.15.183","volume":"15","author":"RM Boomer","year":"2005","unstructured":"Boomer, R. M. et al. Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues. Oligonucleotides 15, 183\u2013195 (2005).","journal-title":"Oligonucleotides"},{"key":"3032_CR228","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","volume":"107","author":"KD Kovacevic","year":"2022","unstructured":"Kovacevic, K. D. et al. The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial. Haematologica 107, 2121\u20132132 (2022).","journal-title":"Haematologica"},{"key":"3032_CR229","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","volume":"137","author":"NJ Ganson","year":"2016","unstructured":"Ganson, N. J. et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J. Allergy Clin. Immunol. 137, 1610\u20131613.e1617 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3032_CR230","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.chembiol.2019.02.001","volume":"26","author":"A Moreno","year":"2019","unstructured":"Moreno, A. et al. Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers. Cell Chem. Biol. 26, 634\u2013644.e633 (2019).","journal-title":"Cell Chem. Biol."},{"key":"3032_CR231","doi-asserted-by":"publisher","first-page":"18902","DOI":"10.1073\/pnas.0509069102","volume":"102","author":"JH Lee","year":"2005","unstructured":"Lee, J. H. et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc. Natl. Acad. Sci. USA. 102, 18902\u201318907 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR232","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrd1677","volume":"4","author":"SL Fine","year":"2005","unstructured":"Fine, S. L., Martin, D. F. & Kirkpatrick, P. Pegaptanib sodium. Nat. Rev. Drug Discov. 4, 187\u2013188 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR233","doi-asserted-by":"crossref","unstructured":"Moon, B. H., Kim, Y. & Kim, S. Y. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int. J. Mol. Sci. 24, 13004 (2023).","DOI":"10.3390\/ijms241613004"},{"key":"3032_CR234","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrd3011","volume":"9","author":"E Wagner","year":"2010","unstructured":"Wagner, E. & Frank, M. M. Therapeutic potential of complement modulation. Nat. Rev. Drug Discov. 9, 43\u201356 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR235","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nri3459","volume":"13","author":"J Ambati","year":"2013","unstructured":"Ambati, J., Atkinson, J. P. & Gelfand, B. D. Immunology of age-related macular degeneration. Nat. Rev. Immunol. 13, 438\u2013451 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"3032_CR236","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe, G. J. et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial. Ophthalmology 128, 576\u2013586 (2021).","journal-title":"Ophthalmology"},{"key":"3032_CR237","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2183\/pjab.91.394","volume":"91","author":"Y Furuichi","year":"2015","unstructured":"Furuichi, Y. Discovery of m(7)G-cap in eukaryotic mRNAs. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 91, 394\u2013409 (2015).","journal-title":"Proc. Jpn Acad. Ser. B Phys. Biol. Sci."},{"key":"3032_CR238","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.trecan.2019.02.011","volume":"5","author":"SL Schuster","year":"2019","unstructured":"Schuster, S. L. & Hsieh, A. C. The untranslated regions of mRNAs in cancer. Trends Cancer 5, 245\u2013262 (2019).","journal-title":"Trends Cancer"},{"key":"3032_CR239","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","volume":"12","author":"PA Krieg","year":"1984","unstructured":"Krieg, P. A. & Melton, D. A. Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 12, 7057\u20137070 (1984).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR240","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465\u20131468 (1990).","journal-title":"Science"},{"key":"3032_CR241","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1546298","volume":"255","author":"GF Jirikowski","year":"1992","unstructured":"Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. & Bloom, F. E. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255, 996\u2013998 (1992).","journal-title":"Science"},{"key":"3032_CR242","first-page":"1397","volume":"55","author":"RM Conry","year":"1995","unstructured":"Conry, R. M. et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55, 1397\u20131400 (1995).","journal-title":"Cancer Res."},{"key":"3032_CR243","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1172\/JCI0214364","volume":"109","author":"A Heiser","year":"2002","unstructured":"Heiser, A. et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409\u2013417 (2002).","journal-title":"J. Clin. Invest."},{"key":"3032_CR244","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-27","volume":"6","author":"R Froissart","year":"2011","unstructured":"Froissart, R. et al. Glucose-6-phosphatase deficiency. Orphanet J. Rare Dis. 6, 27 (2011).","journal-title":"Orphanet J. Rare Dis."},{"key":"3032_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19156-3","volume":"11","author":"L Jiang","year":"2020","unstructured":"Jiang, L. et al. Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia. Nat. Commun. 11, 5339 (2020).","journal-title":"Nat. Commun."},{"key":"3032_CR246","doi-asserted-by":"crossref","unstructured":"Kong, N. et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci. Transl. Med. 11, eaaw1565 (2019).","DOI":"10.1126\/scitranslmed.aaw1565"},{"key":"3032_CR247","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.ymthe.2023.07.022","volume":"31","author":"M Pine","year":"2023","unstructured":"Pine, M. et al. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol. Ther. 31, 2702\u20132714 (2023).","journal-title":"Mol. Ther."},{"key":"3032_CR248","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"3032_CR249","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0268-960X(99)90023-1","volume":"13","author":"D Avigan","year":"1999","unstructured":"Avigan, D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev. 13, 51\u201364 (1999).","journal-title":"Blood Rev."},{"key":"3032_CR250","doi-asserted-by":"crossref","unstructured":"Qdaisat, S. et al. Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading. Nat. Biomed. Eng., 9, 1437\u20131452 (2025).","DOI":"10.1038\/s41551-025-01380-1"},{"key":"3032_CR251","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"3032_CR252","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"3032_CR253","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"3032_CR254","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"3032_CR255","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710\u2013728 (2019).","journal-title":"Mol. Ther."},{"key":"3032_CR256","doi-asserted-by":"crossref","unstructured":"Mala, P. et al. A novel plasmid-based co-tethered transcription platform for high yield, high purity mRNA synthesis. Nucleic Acids Res. 53, (2025).","DOI":"10.1093\/nar\/gkaf1355"},{"key":"3032_CR257","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1021\/acs.accounts.1c00541","volume":"54","author":"L Jia","year":"2021","unstructured":"Jia, L. & Qian, S. B. Therapeutic mRNA engineering from head to tail. Acc. Chem. Res. 54, 4272\u20134282 (2021).","journal-title":"Acc. Chem. Res."},{"key":"3032_CR258","doi-asserted-by":"publisher","first-page":"464321","DOI":"10.1016\/j.chroma.2023.464321","volume":"1707","author":"X Feng","year":"2023","unstructured":"Feng, X. et al. Messenger RNA chromatographic purification: advances and challenges. J. Chromatogr. A 1707, 464321 (2023).","journal-title":"J. Chromatogr. A"},{"key":"3032_CR259","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1038\/nprot.2007.480","volume":"2","author":"SA McKenna","year":"2007","unstructured":"McKenna, S. A. et al. Purification and characterization of transcribed RNAs using gel filtration chromatography. Nat. Protoc. 2, 3270\u20133277 (2007).","journal-title":"Nat. Protoc."},{"key":"3032_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.seppur.2022.122320","volume":"304","author":"N Mencin","year":"2023","unstructured":"Mencin, N. et al. Development and scale-up of oligo-dT monolithic chromatographic column for mRNA capture through understanding of base-pairing interactions. Sep. Purif. Technol. 304, 122320 (2023).","journal-title":"Sep. Purif. Technol."},{"key":"3032_CR261","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","volume":"39","author":"K Kariko","year":"2011","unstructured":"Kariko, K., Muramatsu, H., Ludwig, J. & Weissman, D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 39, e142 (2011).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR262","doi-asserted-by":"crossref","unstructured":"Cho, E. et al. Mesoporous silica particle as an RNA adsorbent for facile purification of in vitro-transcribed RNA. Int. J. Mol. Sci. 24, 12408 (2023).","DOI":"10.3390\/ijms241512408"},{"key":"3032_CR263","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41587-022-01525-6","volume":"41","author":"A Dousis","year":"2023","unstructured":"Dousis, A. et al. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat. Biotechnol. 41, 560\u2013568 (2023).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR264","doi-asserted-by":"publisher","first-page":"33037","DOI":"10.1074\/jbc.M110.155283","volume":"285","author":"F Belanger","year":"2010","unstructured":"Belanger, F., Stepinski, J., Darzynkiewicz, E. & Pelletier, J. Characterization of hMTr1, a human Cap1 2\u2019-O-ribose methyltransferase. J. Biol. Chem. 285, 33037\u201333044 (2010).","journal-title":"J. Biol. Chem."},{"key":"3032_CR265","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1093\/emboj\/cdf678","volume":"21","author":"E van Dijk","year":"2002","unstructured":"van Dijk, E. et al. Human Dcp2: a catalytically active mRNA decapping enzyme located in specific cytoplasmic structures. EMBO J. 21, 6915\u20136924 (2002).","journal-title":"EMBO J."},{"key":"3032_CR266","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1021\/jacs.3c12629","volume":"146","author":"M Warminski","year":"2024","unstructured":"Warminski, M. et al. Trinucleotide mRNA Cap Analogue N6-Benzylated at the Site of Posttranscriptional (m6)A(m) Mark Facilitates mRNA Purification and Confers Superior Translational Properties In Vitro and In Vivo. J. Am. Chem. Soc. 146, 8149\u20138163 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR267","doi-asserted-by":"crossref","unstructured":"Spiewla, T. et al. PolyA tail segmentation improves the stability of the template DNA and increases the translatability of in vitro transcribed mRNA. Nucleic Acids Res. 54, gkaf1412 (2026).","DOI":"10.1093\/nar\/gkaf1412"},{"key":"3032_CR268","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).","journal-title":"Nat. Commun."},{"key":"3032_CR269","doi-asserted-by":"crossref","unstructured":"Yoon, S. et al. Designing 5\u2019 UTR sequences improves the capacity of mRNA therapeutics in preclinical models of aging and obesity. Mol. Ther., 34, 2098\u20132118 (2026).","DOI":"10.1016\/j.ymthe.2025.12.060"},{"key":"3032_CR270","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/15476286.2018.1475178","volume":"15","author":"KH Asrani","year":"2018","unstructured":"Asrani, K. H. et al. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 15, 756\u2013762 (2018).","journal-title":"RNA Biol."},{"key":"3032_CR271","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini von Niessen","year":"2019","unstructured":"Orlandini von Niessen, A. G. et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2019 UTRs identified by cellular library screening. Mol. Ther. 27, 824\u2013836 (2019).","journal-title":"Mol. Ther."},{"key":"3032_CR272","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1248\/bpb.b25-00155","volume":"48","author":"S Sato","year":"2025","unstructured":"Sato, S. et al. Evaluating signal peptide efficiency for extracellular protein secretion for mRNA vaccine design. Biol. Pharm. Bull. 48, 706\u2013712 (2025).","journal-title":"Biol. Pharm. Bull."},{"key":"3032_CR273","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","volume":"22","author":"C Gustafsson","year":"2004","unstructured":"Gustafsson, C., Govindarajan, S. & Minshull, J. Codon bias and heterologous protein expression. Trends Biotechnol. 22, 346\u2013353 (2004).","journal-title":"Trends Biotechnol."},{"key":"3032_CR274","doi-asserted-by":"publisher","first-page":"24075","DOI":"10.1073\/pnas.1908052116","volume":"116","author":"DM Mauger","year":"2019","unstructured":"Mauger, D. M. et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl. Acad. Sci. USA. 116, 24075\u201324083 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR275","doi-asserted-by":"crossref","unstructured":"Ward, M., Richardson, M. & Metkar, M. mRNA folding algorithms for structure and codon optimization. Brief. Bioinform. 26, bbaf386 (2025).","DOI":"10.1093\/bib\/bbaf386"},{"key":"3032_CR276","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","volume":"20","author":"VP Mauro","year":"2014","unstructured":"Mauro, V. P. & Chappell, S. A. A critical analysis of codon optimization in human therapeutics. Trends Mol. Med. 20, 604\u2013613 (2014).","journal-title":"Trends Mol. Med."},{"key":"3032_CR277","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Kariko","year":"2008","unstructured":"Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"3032_CR278","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries, O. et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control Release 217, 337\u2013344 (2015).","journal-title":"J. Control Release"},{"key":"3032_CR279","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","volume":"7","author":"KD Nance","year":"2021","unstructured":"Nance, K. D. & Meier, J. L. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 7, 748\u2013756 (2021).","journal-title":"ACS Cent. Sci."},{"key":"3032_CR280","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"3032_CR281","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"3032_CR282","doi-asserted-by":"publisher","first-page":"e10374","DOI":"10.1002\/btm2.10374","volume":"8","author":"A Curreri","year":"2023","unstructured":"Curreri, A., Sankholkar, D., Mitragotri, S. & Zhao, Z. RNA therapeutics in the clinic. Bioeng. Transl. Med. 8, e10374 (2023).","journal-title":"Bioeng. Transl. Med."},{"key":"3032_CR283","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"3032_CR284","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","volume":"30","author":"GT Szabo","year":"2022","unstructured":"Szabo, G. T., Mahiny, A. J. & Vlatkovic, I. COVID-19 mRNA vaccines: platforms and current developments. Mol. Ther. 30, 1850\u20131868 (2022).","journal-title":"Mol. Ther."},{"key":"3032_CR285","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR286","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/d41573-024-00095-3","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. FDA approves mRNA-based RSV vaccine. Nat. Rev. Drug Discov. 23, 487 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR287","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1093\/cid\/ciaf292","volume":"81","author":"EF Mayer","year":"2026","unstructured":"Mayer, E. F. et al. Safety, tolerability, and immunogenicity of mRNA-1345 in adults at increased risk for respiratory syncytial virus disease aged 18-59 years. Clin. Infect. Dis. 81, e708\u2013e716 (2026).","journal-title":"Clin. Infect. Dis."},{"key":"3032_CR288","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127589","volume":"63","author":"CA Shaw","year":"2025","unstructured":"Shaw, C. A. et al. Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus. Vaccine 63, 127589 (2025).","journal-title":"Vaccine"},{"key":"3032_CR289","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","volume":"169","author":"Y Ishino","year":"1987","unstructured":"Ishino, Y. et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169, 5429\u20135433 (1987).","journal-title":"J. Bacteriol."},{"key":"3032_CR290","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-2958.1995.mmi_17010085.x","volume":"17","author":"FJ Mojica","year":"1995","unstructured":"Mojica, F. J., Ferrer, C., Juez, G. & Rodriguez-Valera, F. Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning. Mol. Microbiol. 17, 85\u201393 (1995).","journal-title":"Mol. Microbiol."},{"key":"3032_CR291","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","volume":"43","author":"R Jansen","year":"2002","unstructured":"Jansen, R., Embden, J. D., Gaastra, W. & Schouls, L. M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 43, 1565\u20131575 (2002).","journal-title":"Mol. Microbiol."},{"key":"3032_CR292","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709\u20131712 (2007).","journal-title":"Science"},{"key":"3032_CR293","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1126\/science.1159689","volume":"321","author":"SJ Brouns","year":"2008","unstructured":"Brouns, S. J. et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321, 960\u2013964 (2008).","journal-title":"Science"},{"key":"3032_CR294","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature09523","volume":"468","author":"JE Garneau","year":"2010","unstructured":"Garneau, J. E. et al. The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67\u201371 (2010).","journal-title":"Nature"},{"key":"3032_CR295","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu, Y. & Li, Z. CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy. Comput Struct. Biotechnol. J. 18, 2401\u20132415 (2020).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"3032_CR296","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature09886","volume":"471","author":"E Deltcheva","year":"2011","unstructured":"Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602\u2013607 (2011).","journal-title":"Nature"},{"key":"3032_CR297","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"3032_CR298","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"3032_CR299","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","volume":"13","author":"G Schwank","year":"2013","unstructured":"Schwank, G. et al. Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13, 653\u2013658 (2013).","journal-title":"Cell Stem Cell"},{"key":"3032_CR300","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","volume":"26","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat. Med. 26, 732\u2013740 (2020).","journal-title":"Nat. Med."},{"key":"3032_CR301","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115141","volume":"44","author":"SN Chu","year":"2025","unstructured":"Chu, S. N. et al. Dual alpha-globin-truncated erythropoietin receptor knockin restores hemoglobin production in alpha-thalassemia-derived erythroid cells. Cell Rep. 44, 115141 (2025).","journal-title":"Cell Rep."},{"key":"3032_CR302","doi-asserted-by":"crossref","unstructured":"Olajossy, B. et al. RIPK4 downregulation reduces ABCG2 expression, increasing BRAF-mutated melanoma cell susceptibility to cisplatin- and doxorubicin-induced apoptosis. Biomolecules 14, 1573 (2024).","DOI":"10.3390\/biom14121573"},{"key":"3032_CR303","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/nar\/gkt076","volume":"41","author":"GL Dianov","year":"2013","unstructured":"Dianov, G. L. & Hubscher, U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. 41, 3483\u20133490 (2013).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR304","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/B978-0-12-801185-0.00008-8","volume":"546","author":"AE Trevino","year":"2014","unstructured":"Trevino, A. E. & Zhang, F. Genome editing using Cas9 nickases. Methods Enzymol. 546, 161\u2013174 (2014).","journal-title":"Methods Enzymol."},{"key":"3032_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35508-7","volume":"14","author":"J Liao","year":"2023","unstructured":"Liao, J. et al. Therapeutic adenine base editing of human hematopoietic stem cells. Nat. Commun. 14, 207 (2023).","journal-title":"Nat. Commun."},{"key":"3032_CR306","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41591-024-03466-w","volume":"31","author":"M An","year":"2025","unstructured":"An, M. et al. In vivo base editing extends lifespan of a humanized mouse model of prion disease. Nat. Med. 31, 1319\u20131328 (2025).","journal-title":"Nat. Med."},{"key":"3032_CR307","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"3032_CR308","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C. et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"3032_CR309","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"3032_CR310","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/cr.2013.122","volume":"23","author":"AW Cheng","year":"2013","unstructured":"Cheng, A. W. et al. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 23, 1163\u20131171 (2013).","journal-title":"Cell Res."},{"key":"3032_CR311","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s11658-023-00508-y","volume":"28","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Synthetic CRISPR\/dCas9-KRAB system driven by specific PSA promoter suppresses malignant biological behavior of prostate cancer cells through negative feedback inhibition of PSA expression. Cell Mol. Biol. Lett. 28, 96 (2023).","journal-title":"Cell Mol. Biol. Lett."},{"key":"3032_CR312","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s12276-023-01128-4","volume":"55","author":"DE Yoon","year":"2023","unstructured":"Yoon, D. E. et al. Precise base editing without unintended indels in human cells and mouse primary myoblasts. Exp. Mol. Med. 55, 2586\u20132595 (2023).","journal-title":"Exp. Mol. Med."},{"key":"3032_CR313","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.molcel.2017.06.035","volume":"67","author":"T Yamano","year":"2017","unstructured":"Yamano, T. et al. Structural basis for the canonical and non-canonical PAM recognition by CRISPR-Cpf1. Mol. Cell 67, 633\u2013645 e633 (2017).","journal-title":"Mol. Cell"},{"key":"3032_CR314","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nature13579","volume":"513","author":"C Anders","year":"2014","unstructured":"Anders, C., Niewoehner, O., Duerst, A. & Jinek, M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 513, 569\u2013573 (2014).","journal-title":"Nature"},{"key":"3032_CR315","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ymthe.2023.11.013","volume":"32","author":"IW Badon","year":"2024","unstructured":"Badon, I. W., Oh, Y., Kim, H. J. & Lee, S. H. Recent application of CRISPR-Cas12 and OMEGA system for genome editing. Mol. Ther. 32, 32\u201343 (2024).","journal-title":"Mol. Ther."},{"key":"3032_CR316","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41587-021-01009-z","volume":"40","author":"DY Kim","year":"2022","unstructured":"Kim, D. Y. et al. Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus. Nat. Biotechnol. 40, 94\u2013102 (2022).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR317","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-018-0011-0","volume":"37","author":"BP Kleinstiver","year":"2019","unstructured":"Kleinstiver, B. P. et al. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat. Biotechnol. 37, 276\u2013282 (2019).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR318","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41587-023-02095-x","volume":"42","author":"R Liang","year":"2024","unstructured":"Liang, R. et al. Prime editing using CRISPR-Cas12a and circular RNAs in human cells. Nat. Biotechnol. 42, 1867\u20131875 (2024).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR319","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.cell.2009.07.040","volume":"139","author":"CR Hale","year":"2009","unstructured":"Hale, C. R. et al. RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell 139, 945\u2013956 (2009).","journal-title":"Cell"},{"key":"3032_CR320","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2016.12.031","volume":"168","author":"L Liu","year":"2017","unstructured":"Liu, L. et al. Two distant catalytic sites are responsible for C2c2 RNase activities. Cell 168, 121\u2013134.e112 (2017).","journal-title":"Cell"},{"key":"3032_CR321","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nature24049","volume":"550","author":"OO Abudayyeh","year":"2017","unstructured":"Abudayyeh, O. O. et al. RNA targeting with CRISPR-Cas13. Nature 550, 280\u2013284 (2017).","journal-title":"Nature"},{"key":"3032_CR322","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.05.025","volume":"81","author":"LC McCoullough","year":"2024","unstructured":"McCoullough, L. C. et al. CRISPR-Cas13b-mediated suppression of HBV replication and protein expression. J. Hepatol. 81, 794\u2013805 (2024).","journal-title":"J. Hepatol."},{"key":"3032_CR323","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55548-5","volume":"16","author":"TX McCallister","year":"2025","unstructured":"McCallister, T. X. et al. A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS\/FTD. Nat. Commun. 16, 460 (2025).","journal-title":"Nat. Commun."},{"key":"3032_CR324","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019\u20131027 (2017).","journal-title":"Science"},{"key":"3032_CR325","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1038\/s44319-024-00283-7","volume":"25","author":"A Pupak","year":"2024","unstructured":"Pupak, A. et al. m(6)A modification of mutant huntingtin RNA promotes the biogenesis of pathogenic huntingtin transcripts. EMBO Rep. 25, 5026\u20135052 (2024).","journal-title":"EMBO Rep."},{"key":"3032_CR326","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46412-7","volume":"15","author":"A Apostolopoulos","year":"2024","unstructured":"Apostolopoulos, A. et al. dCas13-mediated translational repression for accurate gene silencing in mammalian cells. Nat. Commun. 15, 2205 (2024).","journal-title":"Nat. Commun."},{"key":"3032_CR327","doi-asserted-by":"publisher","first-page":"617910","DOI":"10.3389\/fgeed.2020.617910","volume":"2","author":"D Allen","year":"2020","unstructured":"Allen, D., Rosenberg, M. & Hendel, A. Using synthetically engineered guide RNAs to enhance CRISPR genome editing systems in mammalian cells. Front Genome Ed. 2, 617910 (2020).","journal-title":"Front Genome Ed."},{"key":"3032_CR328","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ymeth.2017.04.003","volume":"121\u2013122","author":"MA DeWitt","year":"2017","unstructured":"DeWitt, M. A., Corn, J. E. & Carroll, D. Genome editing via delivery of Cas9 ribonucleoprotein. Methods 121\u2013122, 9\u201315 (2017).","journal-title":"Methods"},{"key":"3032_CR329","doi-asserted-by":"crossref","unstructured":"Xu, C. L., Ruan, M. Z. C., Mahajan, V. B. & Tsang, S. H. Viral delivery systems for CRISPR. Viruses 11, 28 (2019).","DOI":"10.3390\/v11010028"},{"key":"3032_CR330","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.1038\/sj.onc.1209043","volume":"24","author":"AG Uren","year":"2005","unstructured":"Uren, A. G., Kool, J., Berns, A. & Van Lohuizen, M. Retroviral insertional mutagenesis: past, present and future. Oncogene 24, 7656\u20137672 (2005).","journal-title":"Oncogene"},{"key":"3032_CR331","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13578-019-0350-7","volume":"9","author":"Z Hu","year":"2019","unstructured":"Hu, Z. et al. Customized one-step preparation of sgRNA transcription templates via overlapping PCR Using short primers and its application in vitro and in vivo gene editing. Cell Biosci. 9, 87 (2019).","journal-title":"Cell Biosci."},{"key":"3032_CR332","doi-asserted-by":"publisher","first-page":"e2005840","DOI":"10.1371\/journal.pbio.2005840","volume":"16","author":"B Wienert","year":"2018","unstructured":"Wienert, B. et al. In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway. PLoS Biol. 16, e2005840 (2018).","journal-title":"PLoS Biol."},{"key":"3032_CR333","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.tibtech.2019.01.009","volume":"37","author":"SB Moon","year":"2019","unstructured":"Moon, S. B. et al. Improving CRISPR genome editing by engineering guide RNAs. Trends Biotechnol. 37, 870\u2013881 (2019).","journal-title":"Trends Biotechnol."},{"key":"3032_CR334","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1021\/acschembio.3c00140","volume":"18","author":"S Tijaro-Bulla","year":"2023","unstructured":"Tijaro-Bulla, S. et al. Disrupting protein expression with double-clicked sgRNA-Cas9 complexes: a modular approach to CRISPR gene editing. ACS Chem. Biol. 18, 2156\u20132162 (2023).","journal-title":"ACS Chem. Biol."},{"key":"3032_CR335","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nbt.3026","volume":"32","author":"JG Doench","year":"2014","unstructured":"Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262\u20131267 (2014).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR336","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827\u2013832 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR337","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1459-4","volume":"19","author":"G Chuai","year":"2018","unstructured":"Chuai, G. et al. DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biol. 19, 80 (2018).","journal-title":"Genome Biol."},{"key":"3032_CR338","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1039\/C1OB06614E","volume":"10","author":"RN Threlfall","year":"2012","unstructured":"Threlfall, R. N. et al. Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2\u2019-O-methyl oligoribonucleotides. Org. Biomol. Chem. 10, 746\u2013754 (2012).","journal-title":"Org. Biomol. Chem."},{"key":"3032_CR339","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR340","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1021\/acs.biochem.1c00768","volume":"62","author":"DE Ryan","year":"2023","unstructured":"Ryan, D. E. et al. Phosphonoacetate modifications enhance the stability and editing yields of guide RNAs for Cas9 editors. Biochemistry 62, 3512\u20133520 (2023).","journal-title":"Biochemistry"},{"key":"3032_CR341","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179\u20131187 (2017).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR342","doi-asserted-by":"publisher","first-page":"E7110","DOI":"10.1073\/pnas.1520883112","volume":"112","author":"M Rahdar","year":"2015","unstructured":"Rahdar, M. et al. Synthetic CRISPR RNA-Cas9-guided genome editing in human cells. Proc. Natl. Acad. Sci. USA. 112, E7110\u2013E7117 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR343","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28137-7","volume":"13","author":"S Riesenberg","year":"2022","unstructured":"Riesenberg, S. et al. Improved gRNA secondary structures allow editing of target sites resistant to CRISPR-Cas9 cleavage. Nat. Commun. 13, 489 (2022).","journal-title":"Nat. Commun."},{"key":"3032_CR344","doi-asserted-by":"crossref","unstructured":"Schubert, M. S. et al. Chemical modification of CRISPR gRNAs eliminate type I interferon responses in human peripheral blood mononuclear cells. J. Cytokine Biol. 3, 121 (2018).","DOI":"10.4172\/2576-3881.1000121"},{"key":"3032_CR345","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul, H. et al. Exagamglogene autotemcel for severe sickle cell disease. N. Engl. J. Med. 390, 1649\u20131662 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR346","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Exagamglogene autotemcel for transfusion-dependent beta-thalassemia. N. Engl. J. Med. 390, 1663\u20131676 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR347","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1126\/science.1165409","volume":"322","author":"VG Sankaran","year":"2008","unstructured":"Sankaran, V. G. et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322, 1839\u20131842 (2008).","journal-title":"Science"},{"key":"3032_CR348","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1128\/MCB.17.3.1642","volume":"17","author":"MJ Weiss","year":"1997","unstructured":"Weiss, M. J., Yu, C. & Orkin, S. H. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. Mol. Cell Biol. 17, 1642\u20131651 (1997).","journal-title":"Mol. Cell Biol."},{"key":"3032_CR349","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","volume":"25","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat. Med. 25, 776\u2013783 (2019).","journal-title":"Nat. Med."},{"key":"3032_CR350","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR351","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2021.08.035","volume":"573","author":"M Takahashi","year":"2021","unstructured":"Takahashi, M., Seki, M. & Nashimoto, M. A naked antisense oligonucleotide with phosphorothioate linkages is taken up intracellularly more efficiently but functions less effectively. Biochem. Biophys. Res. Commun. 573, 140\u2013144 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3032_CR352","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1093\/nar\/gkz214","volume":"47","author":"E Linnane","year":"2019","unstructured":"Linnane, E. et al. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res. 47, 4375\u20134392 (2019).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR353","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1093\/nar\/gky145","volume":"46","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 46, 3579\u20133594 (2018).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR354","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1093\/nar\/gkr089","volume":"39","author":"E Koller","year":"2011","unstructured":"Koller, E. et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795\u20134807 (2011).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR355","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2024.03.022","volume":"32","author":"S Abbasi","year":"2024","unstructured":"Abbasi, S. et al. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol. Ther. 32, 1266\u20131283 (2024).","journal-title":"Mol. Ther."},{"key":"3032_CR356","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41434-018-0003-1","volume":"25","author":"CJ Stephens","year":"2018","unstructured":"Stephens, C. J. et al. Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR\/Cas9. Gene Ther. 25, 139\u2013156 (2018).","journal-title":"Gene Ther."},{"key":"3032_CR357","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42386-0","volume":"14","author":"LM Riedmayr","year":"2023","unstructured":"Riedmayr, L. M. et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat. Commun. 14, 6578 (2023).","journal-title":"Nat. Commun."},{"key":"3032_CR358","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.2147\/DDDT.S481420","volume":"18","author":"J Goncalves","year":"2024","unstructured":"Goncalves, J. & Caliceti, P. Optimizing pharmacological and immunological properties of therapeutic proteins through PEGylation: investigating key parameters and their impact. Drug Des. Devel Ther. 18, 5041\u20135062 (2024).","journal-title":"Drug Des. Devel Ther."},{"key":"3032_CR359","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.117149","volume":"78","author":"T Rahman Chowdhury","year":"2023","unstructured":"Rahman Chowdhury, T. et al. Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide. Bioorg. Med. Chem. 78, 117149 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"3032_CR360","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chembiol.2004.10.017","volume":"12","author":"PE Burmeister","year":"2005","unstructured":"Burmeister, P. E. et al. Direct in vitro selection of a 2\u2032-O-methyl aptamer to VEGF. Chem. Biol. 12, 25\u201333 (2005).","journal-title":"Chem. Biol."},{"key":"3032_CR361","doi-asserted-by":"publisher","first-page":"12466","DOI":"10.1021\/jacs.5b08069","volume":"137","author":"X Lu","year":"2015","unstructured":"Lu, X. et al. Providing oligonucleotides with steric selectivity by brush-polymer-assisted compaction. J. Am. Chem. Soc. 137, 12466\u201312469 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR362","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113180119","volume":"119","author":"D Wang","year":"2022","unstructured":"Wang, D. et al. Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 119, e2113180119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR363","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1093\/nar\/gkaa164","volume":"48","author":"AE Chappell","year":"2020","unstructured":"Chappell, A. E. et al. Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice. Nucleic Acids Res. 48, 4382\u20134395 (2020).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR364","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/nar\/28.14.2717","volume":"28","author":"MK Bijsterbosch","year":"2000","unstructured":"Bijsterbosch, M. K. et al. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 28, 2717\u20132725 (2000).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR365","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1038\/sj.onc.1208760","volume":"24","author":"BS Herbert","year":"2005","unstructured":"Herbert, B. S. et al. Lipid modification of GRN163, an N3\u2019\u2013>P5\u2019 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24, 5262\u20135268 (2005).","journal-title":"Oncogene"},{"key":"3032_CR366","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 113, 10962\u201310967 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR367","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","volume":"106","author":"T Lehto","year":"2016","unstructured":"Lehto, T., Ezzat, K., Wood, M. J. A. & El Andaloussi, S. Peptides for nucleic acid delivery. Adv. Drug Deliv. Rev. 106, 172\u2013182 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR368","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1093\/nar\/gkq534","volume":"38","author":"X Ming","year":"2010","unstructured":"Ming, X. et al. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res. 38, 6567\u20136576 (2010).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR369","doi-asserted-by":"crossref","unstructured":"Abbasi, S. et al. Spatiotemporal targeting of messenger RNA lipid nanoparticles to the endometrium for the treatment of reproductive disorders. Nat. Nanotechnol. 21, 467\u2013477 (2026).","DOI":"10.1038\/s41565-025-02108-7"},{"key":"3032_CR370","doi-asserted-by":"crossref","unstructured":"Hammond, S. M. et al. Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy. JCI Insight 7, e154142 (2022).","DOI":"10.1172\/jci.insight.154142"},{"key":"3032_CR371","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","volume":"237","author":"T Sugo","year":"2016","unstructured":"Sugo, T. et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J. Control Release 237, 1\u201313 (2016).","journal-title":"J. Control Release"},{"key":"3032_CR372","doi-asserted-by":"crossref","unstructured":"Ryu, Y. et al. Targeted delivery of miR-34a via anti-CD47 antibody conjugates for enhanced cancer immunotherapy in triple negative breast cancer. Small, 21, e04468 (2025).","DOI":"10.1002\/smll.202504468"},{"key":"3032_CR373","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash, T. P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796\u20138807 (2014).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR374","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1021\/acs.jmedchem.2c01337","volume":"66","author":"P Kandasamy","year":"2023","unstructured":"Kandasamy, P. et al. Metabolically stable anomeric linkages containing GalNAc-siRNA conjugates: an interplay among ASGPR, glycosidase, and RISC pathways. J. Med. Chem. 66, 2506\u20132523 (2023).","journal-title":"J. Med. Chem."},{"key":"3032_CR375","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nbt1223","volume":"24","author":"JO McNamara","year":"2006","unstructured":"McNamara, J. O. et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005\u20131015 (2006).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR376","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114542","volume":"390","author":"XR Liao","year":"2026","unstructured":"Liao, X. R. et al. Aptamer-functionalized nanoparticles for CRISPR-Cas9 delivery to circulating malignant cells for therapeutic efficacy evaluation. J. Control Release 390, 114542 (2026).","journal-title":"J. Control Release"},{"key":"3032_CR377","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR378","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","volume":"40","author":"D Sun","year":"2023","unstructured":"Sun, D. & Lu, Z. R. Structure and function of cationic and ionizable lipids for nucleic acid delivery. Pharm. Res. 40, 27\u201346 (2023).","journal-title":"Pharm. Res."},{"key":"3032_CR379","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 121, 12181\u201312277 (2021).","journal-title":"Chem. Rev."},{"key":"3032_CR380","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","volume":"19","author":"F Ferraresso","year":"2022","unstructured":"Ferraresso, F. et al. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells. Mol. Pharm. 19, 2175\u20132182 (2022).","journal-title":"Mol. Pharm."},{"key":"3032_CR381","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"3032_CR382","doi-asserted-by":"crossref","unstructured":"Paramasivam, P. et al. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. J. Cell Biol. 221, e202110137 (2022).","DOI":"10.1083\/jcb.202110137"},{"key":"3032_CR383","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14527-2","volume":"11","author":"S Patel","year":"2020","unstructured":"Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).","journal-title":"Nat. Commun."},{"key":"3032_CR384","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ijpharm.2005.05.005","volume":"300","author":"WX Ding","year":"2005","unstructured":"Ding, W. X. et al. Cholesteryl hemisuccinate as a membrane stabilizer in dipalmitoylphosphatidylcholine liposomes containing saikosaponin-d. Int. J. Pharm. 300, 38\u201347 (2005).","journal-title":"Int. J. Pharm."},{"key":"3032_CR385","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/tra.12576","volume":"19","author":"SM Lu","year":"2018","unstructured":"Lu, S. M. & Fairn, G. D. 7-Ketocholesterol impairs phagocytosis and efferocytosis via dysregulation of phosphatidylinositol 4,5-bisphosphate. Traffic 19, 591\u2013604 (2018).","journal-title":"Traffic"},{"key":"3032_CR386","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk, J. S. et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR387","doi-asserted-by":"publisher","first-page":"114726","DOI":"10.1016\/j.ejpb.2025.114726","volume":"212","author":"A Borah","year":"2025","unstructured":"Borah, A. et al. From in vitro to in vivo: the dominant role of PEG-Lipids in LNP performance. Eur. J. Pharm. Biopharm. 212, 114726 (2025).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"3032_CR388","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101457","volume":"33","author":"M Jester","year":"2025","unstructured":"Jester, M. et al. Ionizable lipid nanoparticles with functionalized PEG-lipids increase retention in the tumor microenvironment. Mol. Ther. Methods Clin. Dev. 33, 101457 (2025).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3032_CR389","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1039\/D1BM01454D","volume":"10","author":"E Alvarez-Benedicto","year":"2022","unstructured":"Alvarez-Benedicto, E. et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater. Sci. 10, 549\u2013559 (2022).","journal-title":"Biomater. Sci."},{"key":"3032_CR390","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413016","volume":"12","author":"K Iwakawa","year":"2025","unstructured":"Iwakawa, K. et al. Cubic phase-inducible zwitterionic phospholipids improve the functional delivery of mRNA. Adv. Sci. 12, e2413016 (2025).","journal-title":"Adv. Sci."},{"key":"3032_CR391","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","volume":"16","author":"MJ Wagner","year":"2017","unstructured":"Wagner, M. J. et al. Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA). Mol. Cancer Ther. 16, 1114\u20131123 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"3032_CR392","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","volume":"156","author":"AS Piotrowski-Daspit","year":"2020","unstructured":"Piotrowski-Daspit, A. S., Kauffman, A. C., Bracaglia, L. G. & Saltzman, W. M. Polymeric vehicles for nucleic acid delivery. Adv. Drug Deliv. Rev. 156, 119\u2013132 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR393","doi-asserted-by":"crossref","unstructured":"Cai, X. et al. Cationic polymers as transfection reagents for nucleic acid delivery. Pharmaceutics 15, 1502 (2023).","DOI":"10.3390\/pharmaceutics15051502"},{"key":"3032_CR394","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202200409","volume":"23","author":"Y Jin","year":"2023","unstructured":"Jin, Y. et al. Synthesis and application of low molecular weight PEI-based copolymers for siRNA delivery with smart polymer blends. Macromol. Biosci. 23, e2200409 (2023).","journal-title":"Macromol. Biosci."},{"key":"3032_CR395","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.ymthe.2025.01.037","volume":"33","author":"B Liu","year":"2025","unstructured":"Liu, B. et al. PBAE-PEG-based lipid nanoparticles for lung cell-specific gene delivery. Mol. Ther. 33, 1154\u20131165 (2025).","journal-title":"Mol. Ther."},{"key":"3032_CR396","doi-asserted-by":"crossref","unstructured":"Alsaab, H. O. et al. PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases. Pharmaceutics 14, 2728 (2022).","DOI":"10.3390\/pharmaceutics14122728"},{"key":"3032_CR397","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1158\/0008-5472.CAN-17-3871","volume":"78","author":"Y Byeon","year":"2018","unstructured":"Byeon, Y. et al. CD44-targeting PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. Cancer Res. 78, 6247\u20136256 (2018).","journal-title":"Cancer Res."},{"key":"3032_CR398","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1021\/acs.molpharmaceut.5c00414","volume":"22","author":"Y Yagi","year":"2025","unstructured":"Yagi, Y. et al. Intravenous administration of antisense oligonucleotide incorporated into PLGA nanoparticles alters the pattern of organ distribution and gene knockdown effects. Mol. Pharm. 22, 4794\u20134803 (2025).","journal-title":"Mol. Pharm."},{"key":"3032_CR399","doi-asserted-by":"publisher","first-page":"275","DOI":"10.34172\/apb.2023.030","volume":"13","author":"MY Al-Absi","year":"2023","unstructured":"Al-Absi, M. Y., Caprifico, A. E. & Calabrese, G. Chitosan and its structural modifications for siRNA delivery. Adv. Pharm. Bull. 13, 275\u2013282 (2023).","journal-title":"Adv. Pharm. Bull."},{"key":"3032_CR400","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1517\/17425247.2016.1134486","volume":"13","author":"Y Jiang","year":"2016","unstructured":"Jiang, Y. et al. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin. Drug Deliv. 13, 547\u2013559 (2016).","journal-title":"Expert Opin. Drug Deliv."},{"key":"3032_CR401","doi-asserted-by":"publisher","first-page":"32998","DOI":"10.1021\/acsomega.5c02145","volume":"10","author":"D Hwang","year":"2025","unstructured":"Hwang, D. et al. Gold nanoparticle-mRNA conjugates encapsulated in lipid nanoparticles for coordinated codelivery of multiple mRNAs. ACS Omega 10, 32998\u201333007 (2025).","journal-title":"ACS Omega"},{"key":"3032_CR402","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/smll.201200028","volume":"8","author":"HK Na","year":"2012","unstructured":"Na, H. K. et al. Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small 8, 1752\u20131761 (2012).","journal-title":"Small"},{"key":"3032_CR403","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.addr.2012.07.002","volume":"65","author":"D Sun","year":"2013","unstructured":"Sun, D. et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv. Drug Deliv. Rev. 65, 342\u2013347 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR404","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10787-022-01115-7","volume":"31","author":"S Sadeghi","year":"2023","unstructured":"Sadeghi, S. et al. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology 31, 145\u2013169 (2023).","journal-title":"Inflammopharmacology"},{"key":"3032_CR405","doi-asserted-by":"publisher","first-page":"34211","DOI":"10.1074\/jbc.M109.041152","volume":"284","author":"I Parolini","year":"2009","unstructured":"Parolini, I. et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284, 34211\u201334222 (2009).","journal-title":"J. Biol. Chem."},{"key":"3032_CR406","doi-asserted-by":"publisher","first-page":"22258","DOI":"10.1074\/jbc.M114.588046","volume":"289","author":"T Tian","year":"2014","unstructured":"Tian, T. et al. Exosome uptake through clathrin-mediated endocytosis and macropinocytosis and mediating miR-21 delivery. J. Biol. Chem. 289, 22258\u201322267 (2014).","journal-title":"J. Biol. Chem."},{"key":"3032_CR407","doi-asserted-by":"publisher","first-page":"344","DOI":"10.20517\/evcna.2024.19","volume":"5","author":"L Hagedorn","year":"2024","unstructured":"Hagedorn, L., Jurgens, D. C., Merkel, O. M. & Winkeljann, B. Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design. Extracell. Vesicles Circ. Nucl. Acids 5, 344\u2013357 (2024).","journal-title":"Extracell. Vesicles Circ. Nucl. Acids"},{"key":"3032_CR408","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1089\/neu.2020.7575","volume":"38","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. MiR-17-92 cluster-enriched exosomes derived from human bone marrow mesenchymal stromal cells improve tissue and functional recovery in rats after traumatic brain injury. J. Neurotrauma 38, 1535\u20131550 (2021).","journal-title":"J. Neurotrauma"},{"key":"3032_CR409","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1002\/anie.201913700","volume":"59","author":"G Wu","year":"2020","unstructured":"Wu, G. et al. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angew. Chem. Int. Ed. Engl. 59, 4068\u20134074 (2020).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"3032_CR410","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp9435","volume":"8","author":"T Wan","year":"2022","unstructured":"Wan, T. et al. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci. Adv. 8, eabp9435 (2022).","journal-title":"Sci. Adv."},{"key":"3032_CR411","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim, S. M. et al. Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J. Control Release 266, 8\u201316 (2017).","journal-title":"J. Control Release"},{"key":"3032_CR412","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.7150\/thno.49874","volume":"11","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics 11, 2953\u20132965 (2021).","journal-title":"Theranostics"},{"key":"3032_CR413","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri, V. S. et al. Engineered exosomes with Kras(G12D) specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat. Commun. 16, 8696 (2025).","journal-title":"Nat. Commun."},{"key":"3032_CR414","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.biomaterials.2016.03.025","volume":"91","author":"S Hamzei Taj","year":"2016","unstructured":"Hamzei Taj, S. et al. MiRNA-124 induces neuroprotection and functional improvement after focal cerebral ischemia. Biomaterials 91, 151\u2013165 (2016).","journal-title":"Biomaterials"},{"key":"3032_CR415","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1073\/pnas.81.17.5523","volume":"81","author":"V Pachnis","year":"1984","unstructured":"Pachnis, V., Belayew, A. & Tilghman, S. M. Locus unlinked to alpha-fetoprotein under the control of the murine raf and Rif genes. Proc. Natl. Acad. Sci. USA. 81, 5523\u20135527 (1984).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR416","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/0092-8674(92)90520-M","volume":"71","author":"CJ Brown","year":"1992","unstructured":"Brown, C. J. et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell 71, 527\u2013542 (1992).","journal-title":"Cell"},{"key":"3032_CR417","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","volume":"32","author":"N Amodio","year":"2018","unstructured":"Amodio, N. et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia 32, 1948\u20131957 (2018).","journal-title":"Leukemia"},{"key":"3032_CR418","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3892\/ijo.2016.3377","volume":"48","author":"L Chen","year":"2016","unstructured":"Chen, L. et al. Lentiviral-mediated overexpression of long non-coding RNA GAS5 reduces invasion by mediating MMP2 expression and activity in human melanoma cells. Int. J. Oncol. 48, 1509\u20131518 (2016).","journal-title":"Int. J. Oncol."},{"key":"3032_CR419","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cell.2011.09.028","volume":"147","author":"M Cesana","year":"2011","unstructured":"Cesana, M. et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147, 358\u2013369 (2011).","journal-title":"Cell"},{"key":"3032_CR420","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/ng.848","volume":"43","author":"T Hung","year":"2011","unstructured":"Hung, T. et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat. Genet. 43, 621\u2013629 (2011).","journal-title":"Nat. Genet."},{"key":"3032_CR421","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00404-017-4293-0","volume":"295","author":"O Lavie","year":"2017","unstructured":"Lavie, O. et al. A phase 1\/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian\/peritoneal cancer. Arch. Gynecol. Obstet. 295, 751\u2013761 (2017).","journal-title":"Arch. Gynecol. Obstet."},{"key":"3032_CR422","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.juro.2013.12.011","volume":"191","author":"ON Gofrit","year":"2014","unstructured":"Gofrit, O. N. et al. DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J. Urol. 191, 1697\u20131702 (2014).","journal-title":"J. Urol."},{"key":"3032_CR423","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05715-5","volume":"22","author":"SS Sarkar","year":"2024","unstructured":"Sarkar, S. S., Sharma, M., Saproo, S. & Naidu, S. LINC01116-dependent upregulation of RNA polymerase I transcription drives oncogenic phenotypes in lung adenocarcinoma. J. Transl. Med. 22, 904 (2024).","journal-title":"J. Transl. Med."},{"key":"3032_CR424","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/CIRCULATIONAHA.123.063760","volume":"148","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. INKILN is a novel long noncoding RNA promoting vascular smooth muscle inflammation via scaffolding MKL1 and USP10. Circulation 148, 47\u201367 (2023).","journal-title":"Circulation"},{"key":"3032_CR425","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jconrel.2022.01.026","volume":"343","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy. J. Control Release 343, 107\u2013117 (2022).","journal-title":"J. Control Release"},{"key":"3032_CR426","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/280339a0","volume":"280","author":"MT Hsu","year":"1979","unstructured":"Hsu, M. T. & Coca-Prados, M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 280, 339\u2013340 (1979).","journal-title":"Nature"},{"key":"3032_CR427","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0092-8674(91)90244-S","volume":"64","author":"JM Nigro","year":"1991","unstructured":"Nigro, J. M. et al. Scrambled exons. Cell 64, 607\u2013613 (1991).","journal-title":"Cell"},{"key":"3032_CR428","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.1158441","volume":"320","author":"U Nagalakshmi","year":"2008","unstructured":"Nagalakshmi, U. et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 320, 1344\u20131349 (2008).","journal-title":"Science"},{"key":"3032_CR429","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.699","volume":"5","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Circular RNAs in human diseases. MedComm 5, e699 (2024).","journal-title":"MedComm"},{"key":"3032_CR430","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","volume":"26","author":"E O\u2019Leary","year":"2025","unstructured":"O\u2019Leary, E. et al. The therapeutic potential of circular RNAs. Nat. Rev. Genet. 26, 230\u2013244 (2025).","journal-title":"Nat. Rev. Genet."},{"key":"3032_CR431","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2504904123","volume":"123","author":"Y Lin","year":"2026","unstructured":"Lin, Y. et al. Circular RNA-based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 123, e2504904123 (2026).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR432","doi-asserted-by":"publisher","first-page":"114826","DOI":"10.1016\/j.addr.2023.114826","volume":"197","author":"T Loan Young","year":"2023","unstructured":"Loan Young, T., Chang Wang, K., James Varley, A. & Li, B. Clinical delivery of circular RNA: Lessons learned from RNA drug development. Adv. Drug Deliv. Rev. 197, 114826 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR433","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06800-z","volume":"23","author":"S Xiong","year":"2025","unstructured":"Xiong, S. et al. PLGA-microspheres carried circ_0003251 alleviate intervertebral disc degeneration via the miR-637\/AKT1 axis. J. Transl. Med. 23, 840 (2025).","journal-title":"J. Transl. Med."},{"key":"3032_CR434","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02272-3","volume":"24","author":"M Peng","year":"2025","unstructured":"Peng, M. et al. Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation. Mol. Cancer 24, 67 (2025).","journal-title":"Mol. Cancer"},{"key":"3032_CR435","doi-asserted-by":"crossref","unstructured":"Papaioannou, D. et al. circPCMTD1: a protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias. Blood, 147, 2375\u20132387 (2026).","DOI":"10.1182\/blood.2025031129"},{"key":"3032_CR436","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1801","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. A novel peptide encoded by circ-SLC9A6 promotes lipid dyshomeostasis through the regulation of H4K16ac-mediated CD36 transcription in NAFLD. Clin. Transl. Med. 14, e1801 (2024).","journal-title":"Clin. Transl. Med."},{"key":"3032_CR437","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","volume":"74","author":"RA Wesselhoeft","year":"2019","unstructured":"Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell 74, 508\u2013520.e504 (2019).","journal-title":"Mol. Cell"},{"key":"3032_CR438","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.7536344","volume":"268","author":"CY Chen","year":"1995","unstructured":"Chen, C. Y. & Sarnow, P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. Science 268, 415\u2013417 (1995).","journal-title":"Science"},{"key":"3032_CR439","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/cr.2017.31","volume":"27","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 27, 626\u2013641 (2017).","journal-title":"Cell Res."},{"key":"3032_CR440","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53242-0","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice. Nat. Commun. 15, 8932 (2024).","journal-title":"Nat. Commun."},{"key":"3032_CR441","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63343-z","volume":"16","author":"J Suo","year":"2025","unstructured":"Suo, J. et al. Circular RNA-based protein replacement therapy mitigates osteoarthritis in male mice. Nat. Commun. 16, 8480 (2025).","journal-title":"Nat. Commun."},{"key":"3032_CR442","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","volume":"625","author":"D Huang","year":"2024","unstructured":"Huang, D. et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature 625, 593\u2013602 (2024).","journal-title":"Nature"},{"key":"3032_CR443","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2025.115527","volume":"396","author":"MA Hintermayer","year":"2026","unstructured":"Hintermayer, M. A. et al. A synthetic circular RNA targeting miR-340-5p promotes optic nerve regeneration and retinal ganglion cell survival following axotomy. Exp. Neurol. 396, 115527 (2026).","journal-title":"Exp. Neurol."},{"key":"3032_CR444","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jhep.2024.11.052","volume":"82","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. A read-through circular RNA RCRIN inhibits metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 82, 1068\u20131079 (2025).","journal-title":"J. Hepatol."},{"key":"3032_CR445","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymeth.2021.02.020","volume":"196","author":"P Obi","year":"2021","unstructured":"Obi, P. & Chen, Y. G. The design and synthesis of circular RNAs. Methods 196, 85\u2013103 (2021).","journal-title":"Methods"},{"key":"3032_CR446","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.nbt.2025.12.004","volume":"91","author":"YC Kim","year":"2026","unstructured":"Kim, Y. C. et al. Splint-free circular RNA synthesis via RNA secondary structure-guided ligation. N. Biotechnol. 91, 120\u2013126 (2026).","journal-title":"N. Biotechnol."},{"key":"3032_CR447","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1093\/nar\/20.20.5357","volume":"20","author":"M Puttaraju","year":"1992","unstructured":"Puttaraju, M. & Been, M. D. Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons. Nucleic Acids Res. 20, 5357\u20135364 (1992).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR448","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).","journal-title":"Nat. Commun."},{"key":"3032_CR449","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1093\/nar\/gkad554","volume":"51","author":"J Cui","year":"2023","unstructured":"Cui, J. et al. A precise and efficient circular RNA synthesis system based on a ribozyme derived from Tetrahymena thermophila. Nucleic Acids Res. 51, e78 (2023).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR450","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s12276-024-01251-w","volume":"56","author":"SW Choi","year":"2024","unstructured":"Choi, S. W. & Nam, J. W. Optimal design of synthetic circular RNAs. Exp. Mol. Med. 56, 1281\u20131292 (2024).","journal-title":"Exp. Mol. Med."},{"key":"3032_CR451","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2505718122","volume":"122","author":"KL Swingle","year":"2025","unstructured":"Swingle, K. L. et al. Circular RNA lipid nanoparticle vaccine against SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 122, e2505718122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR452","doi-asserted-by":"publisher","first-page":"17337","DOI":"10.1073\/pnas.0607015103","volume":"103","author":"LC Li","year":"2006","unstructured":"Li, L. C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA. 103, 17337\u201317342 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR453","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nchembio860","volume":"3","author":"BA Janowski","year":"2007","unstructured":"Janowski, B. A. et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3, 166\u2013173 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"3032_CR454","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCRESAHA.109.200774","volume":"105","author":"MP Turunen","year":"2009","unstructured":"Turunen, M. P. et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ. Res. 105, 604\u2013609 (2009).","journal-title":"Circ. Res."},{"key":"3032_CR455","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ymthe.2017.07.018","volume":"25","author":"J Voutila","year":"2017","unstructured":"Voutila, J. et al. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol. Ther. 25, 2705\u20132714 (2017).","journal-title":"Mol. Ther."},{"key":"3032_CR456","doi-asserted-by":"publisher","first-page":"7736","DOI":"10.1093\/nar\/gkq648","volume":"38","author":"Y Chu","year":"2010","unstructured":"Chu, Y. et al. Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res. 38, 7736\u20137748 (2010).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR457","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1093\/nar\/gkw076","volume":"44","author":"X Meng","year":"2016","unstructured":"Meng, X. et al. Small activating RNA binds to the genomic target site in a seed-region-dependent manner. Nucleic Acids Res. 44, 2274\u20132282 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR458","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/cr.2016.22","volume":"26","author":"V Portnoy","year":"2016","unstructured":"Portnoy, V. et al. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 26, 320\u2013335 (2016).","journal-title":"Cell Res."},{"key":"3032_CR459","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1261\/rna.043968.113","volume":"20","author":"X Zhang","year":"2014","unstructured":"Zhang, X., Li, H., Burnett, J. C. & Rossi, J. J. The role of antisense long noncoding RNA in small RNA-triggered gene activation. RNA 20, 1916\u20131928 (2014).","journal-title":"RNA"},{"key":"3032_CR460","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1093\/nar\/gkn693","volume":"36","author":"T Ohrt","year":"2008","unstructured":"Ohrt, T. et al. Fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy reveal the cytoplasmic origination of loaded nuclear RISC in vivo in human cells. Nucleic Acids Res. 36, 6439\u20136449 (2008).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR461","doi-asserted-by":"publisher","first-page":"10270","DOI":"10.1074\/jbc.C113.541417","volume":"289","author":"Y Wei","year":"2014","unstructured":"Wei, Y. et al. Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J. Biol. Chem. 289, 10270\u201310275 (2014).","journal-title":"J. Biol. Chem."},{"key":"3032_CR462","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.celrep.2016.04.034","volume":"15","author":"P Chaluvally-Raghavan","year":"2016","unstructured":"Chaluvally-Raghavan, P. et al. Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep. 15, 1493\u20131504 (2016).","journal-title":"Cell Rep."},{"key":"3032_CR463","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/nar\/gkr934","volume":"40","author":"V Huang","year":"2012","unstructured":"Huang, V. et al. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 40, 1695\u20131707 (2012).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR464","doi-asserted-by":"crossref","unstructured":"Musiala-Kierklo, N., Plewka, P., Jasiok, A. & Stepniak-Konieczna, E. Promoter-targeted small RNA duplexes increase MBNL1 transcription and mitigate myotonic dystrophy-associated spliceopathy. Nucleic Acids Res. 53, gkaf756 (2025).","DOI":"10.1093\/nar\/gkaf756"},{"key":"3032_CR465","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1089\/nat.2021.0115","volume":"32","author":"P Andrikakou","year":"2022","unstructured":"Andrikakou, P. et al. Enhancing SIRT1 gene expression using small activating RNAs: a novel approach for reversing metabolic syndrome. Nucleic Acid Ther. 32, 486\u2013496 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"3032_CR466","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3389\/fimmu.2019.01804","volume":"10","author":"W Wang","year":"2019","unstructured":"Wang, W., Xia, X., Mao, L. & Wang, S. The CCAAT\/enhancer-binding protein family: its roles in MDSC expansion and function. Front. Immunol. 10, 1804 (2019).","journal-title":"Front. Immunol."},{"key":"3032_CR467","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1038\/onc.2017.151","volume":"36","author":"AR Lourenco","year":"2017","unstructured":"Lourenco, A. R. & Coffer, P. J. A tumor suppressor role for C\/EBPalpha in solid tumors: more than fat and blood. Oncogene 36, 5221\u20135230 (2017).","journal-title":"Oncogene"},{"key":"3032_CR468","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-21-0986","volume":"27","author":"A Hashimoto","year":"2021","unstructured":"Hashimoto, A. et al. Upregulation of C\/EBPalpha inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin. Cancer Res. 27, 5961\u20135978 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3032_CR469","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-981-10-4310-9_16","volume":"983","author":"MR Kang","year":"2017","unstructured":"Kang, M. R. et al. Development of therapeutic dsP21-322 for cancer treatment. Adv. Exp. Med. Biol. 983, 217\u2013229 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"3032_CR470","doi-asserted-by":"publisher","first-page":"22650","DOI":"10.1021\/acs.jmedchem.5c01648","volume":"68","author":"JP Desaulniers","year":"2025","unstructured":"Desaulniers, J. P. et al. Exploring chemically modified short activating RNAs to increase stability against nucleases and enhance gene activation. J. Med. Chem. 68, 22650\u201322664 (2025).","journal-title":"J. Med. Chem."},{"key":"3032_CR471","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113638","volume":"382","author":"L Xu","year":"2025","unstructured":"Xu, L. et al. Poly-lysine-modified recombinant protein nanocages for effective delivery of small activating RNA. J. Control Release 382, 113638 (2025).","journal-title":"J. Control Release"},{"key":"3032_CR472","doi-asserted-by":"publisher","first-page":"114488","DOI":"10.1016\/j.jconrel.2025.114488","volume":"389","author":"Y Liu","year":"2026","unstructured":"Liu, Y. et al. Bioswitchable intracellular delivery of small activating RNA by tetrahedral framework nucleic acid: application to p21-mediated anti-tumor therapy. J. Control Release 389, 114488 (2026).","journal-title":"J. Control Release"},{"key":"3032_CR473","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics - challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629\u2013651 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3032_CR474","doi-asserted-by":"publisher","first-page":"115052","DOI":"10.1016\/j.addr.2023.115052","volume":"201","author":"S Ranjbar","year":"2023","unstructured":"Ranjbar, S., Zhong, X. B., Manautou, J. & Lu, X. A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics. Adv. Drug Deliv. Rev. 201, 115052 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR475","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41580-019-0136-0","volume":"20","author":"LR Ganser","year":"2019","unstructured":"Ganser, L. R., Kelly, M. L., Herschlag, D. & Al-Hashimi, H. M. The roles of structural dynamics in the cellular functions of RNAs. Nat. Rev. Mol. Cell Biol. 20, 474\u2013489 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3032_CR476","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.chembiol.2023.12.010","volume":"31","author":"R Bose","year":"2024","unstructured":"Bose, R., Saleem, I. & Mustoe, A. M. Causes, functions, and therapeutic possibilities of RNA secondary structure ensembles and alternative states. Cell Chem. Biol. 31, 17\u201335 (2024).","journal-title":"Cell Chem. Biol."},{"key":"3032_CR477","doi-asserted-by":"publisher","first-page":"9716","DOI":"10.1093\/nar\/gkx617","volume":"45","author":"D Incarnato","year":"2017","unstructured":"Incarnato, D. et al. In vivo probing of nascent RNA structures reveals principles of cotranscriptional folding. Nucleic Acids Res. 45, 9716\u20139725 (2017).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR478","first-page":"9956","volume":"44","author":"P Dallaire","year":"2016","unstructured":"Dallaire, P. et al. Structural dynamics control the MicroRNA maturation pathway. Nucleic Acids Res. 44, 9956\u20139964 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR479","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04415-1","volume":"9","author":"R Yamagami","year":"2018","unstructured":"Yamagami, R., Bingaman, J. L., Frankel, E. A. & Bevilacqua, P. C. Cellular conditions of weakly chelated magnesium ions strongly promote RNA stability and catalysis. Nat. Commun. 9, 2149 (2018).","journal-title":"Nat. Commun."},{"key":"3032_CR480","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1261\/rna.070466.119","volume":"25","author":"AA O\u2019Connell","year":"2019","unstructured":"O\u2019Connell, A. A. et al. Thermodynamic examination of pH and magnesium effect on U6 RNA internal loop. RNA 25, 1779\u20131792 (2019).","journal-title":"RNA"},{"key":"3032_CR481","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1021\/ja513080v","volume":"137","author":"C Roost","year":"2015","unstructured":"Roost, C. et al. Structure and thermodynamics of N6-methyladenosine in RNA: a spring-loaded base modification. J. Am. Chem. Soc. 137, 2107\u20132115 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"3032_CR482","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01509-w","volume":"22","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. Understanding immune microenvironment alterations in the brain to improve the diagnosis and treatment of diverse brain diseases. Cell Commun. Signal 22, 132 (2024).","journal-title":"Cell Commun. Signal"},{"key":"3032_CR483","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40164-025-00648-1","volume":"14","author":"YP Ding","year":"2025","unstructured":"Ding, Y. P., Liu, C. C. & Yu, K. D. RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond. Exp. Hematol. Oncol. 14, 48 (2025).","journal-title":"Exp. Hematol. Oncol."},{"key":"3032_CR484","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-023-01537-x","volume":"21","author":"H Guo","year":"2023","unstructured":"Guo, H. et al. Hypoxia induces alterations in tRNA modifications involved in translational control. BMC Biol. 21, 39 (2023).","journal-title":"BMC Biol."},{"key":"3032_CR485","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/15476286.2020.1867797","volume":"18","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Okada, S. & Sakurai, M. Adenosine-to-inosine RNA editing in neurological development and disease. RNA Biol. 18, 999\u20131013 (2021).","journal-title":"RNA Biol."},{"key":"3032_CR486","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","volume":"13","author":"H Jiang","year":"2004","unstructured":"Jiang, H. et al. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13, 3079\u20133088 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"3032_CR487","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.drudis.2018.08.004","volume":"23","author":"SJ Overby","year":"2018","unstructured":"Overby, S. J., Cerro-Herreros, E., Llamusi, B. & Artero, R. RNA-mediated therapies in myotonic dystrophy. Drug Discov. Today 23, 2013\u20132022 (2018).","journal-title":"Drug Discov. Today"},{"key":"3032_CR488","doi-asserted-by":"publisher","first-page":"e1001074","DOI":"10.1371\/journal.pgen.1001074","volume":"6","author":"M Halvorsen","year":"2010","unstructured":"Halvorsen, M., Martin, J. S., Broadaway, S. & Laederach, A. Disease-associated mutations that alter the RNA structural ensemble. PLoS Genet. 6, e1001074 (2010).","journal-title":"PLoS Genet."},{"key":"3032_CR489","doi-asserted-by":"publisher","first-page":"e2112677119","DOI":"10.1073\/pnas.2112677119","volume":"119","author":"Q Vicens","year":"2022","unstructured":"Vicens, Q. & Kieft, J. S. Thoughts on how to think (and talk) about RNA structure. Proc. Natl. Acad. Sci. USA. 119, e2112677119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR490","doi-asserted-by":"publisher","first-page":"e2300319","DOI":"10.1002\/adhm.202300319","volume":"12","author":"TB Gandek","year":"2023","unstructured":"Gandek, T. B., van der Koog, L. & Nagelkerke, A. A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles. Adv. Health. Mater. 12, e2300319 (2023).","journal-title":"Adv. Health. Mater."},{"key":"3032_CR491","doi-asserted-by":"publisher","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl. Acad. Sci. USA. 121, e2307800120 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3032_CR492","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jconrel.2016.12.005","volume":"246","author":"M Chiper","year":"2017","unstructured":"Chiper, M. et al. Self-aggregating 1.8kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides. J. Control Release 246, 60\u201370 (2017).","journal-title":"J. Control Release"},{"key":"3032_CR493","doi-asserted-by":"publisher","first-page":"102506","DOI":"10.1016\/j.cbpa.2024.102506","volume":"81","author":"M Grau","year":"2024","unstructured":"Grau, M. & Wagner, E. Strategies and mechanisms for endosomal escape of therapeutic nucleic acids. Curr. Opin. Chem. Biol. 81, 102506 (2024).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"3032_CR494","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172\u2013176 (2010).","journal-title":"Nat. Biotechnol."},{"key":"3032_CR495","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15300-1","volume":"11","author":"H Du Rietz","year":"2020","unstructured":"Du Rietz, H. et al. Imaging small molecule-induced endosomal escape of siRNA. Nat. Commun. 11, 1809 (2020).","journal-title":"Nat. Commun."},{"key":"3032_CR496","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jconrel.2022.06.039","volume":"348","author":"M Kim","year":"2022","unstructured":"Kim, M. et al. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J. Control Release 348, 893\u2013910 (2022).","journal-title":"J. Control Release"},{"key":"3032_CR497","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/acs.bioconjchem.5c00205","volume":"36","author":"R Das","year":"2025","unstructured":"Das, R. et al. Multicheckpoint cellular targeting of siRNAs using antibody-directed lipid-polymer hybrid nanoparticles. Bioconjug Chem. 36, 1527\u20131540 (2025).","journal-title":"Bioconjug Chem."},{"key":"3032_CR498","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaci.2017.04.049","volume":"141","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. et al. Mannose receptor modulates macrophage polarization and allergic inflammation through miR-511-3p. J. Allergy Clin. Immunol. 141, 350\u2013364 e358 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3032_CR499","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jconrel.2023.11.034","volume":"365","author":"W Tu","year":"2024","unstructured":"Tu, W. et al. Effective delivery of miR-511-3p with mannose-decorated exosomes with RNA nanoparticles confers protection against asthma. J. Control Release 365, 602\u2013616 (2024).","journal-title":"J. Control Release"},{"key":"3032_CR500","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jconrel.2022.05.020","volume":"347","author":"SK Patel","year":"2022","unstructured":"Patel, S. K. et al. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. J. Control Release 347, 521\u2013532 (2022).","journal-title":"J. Control Release"},{"key":"3032_CR501","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/nar\/gkx1165","volume":"46","author":"A Reyes","year":"2018","unstructured":"Reyes, A. & Huber, W. Alternative start and termination sites of transcription drive most transcript isoform differences across human tissues. Nucleic Acids Res. 46, 582\u2013592 (2018).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR502","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nrm.2016.116","volume":"18","author":"B Tian","year":"2017","unstructured":"Tian, B. & Manley, J. L. Alternative polyadenylation of mRNA precursors. Nat. Rev. Mol. Cell Biol. 18, 18\u201330 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3032_CR503","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05212-x","volume":"13","author":"S Adhikary","year":"2022","unstructured":"Adhikary, S. et al. ZMYND8 suppresses MAPT213 LncRNA transcription to promote neuronal differentiation. Cell Death Dis. 13, 766 (2022).","journal-title":"Cell Death Dis."},{"key":"3032_CR504","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab153","volume":"5","author":"EI Ramos","year":"2021","unstructured":"Ramos, E. I. et al. Characterization of the testis-specific LINC01016 gene reveals isoform-specific roles in controlling biological processes. J. Endocr. Soc. 5, bvab153 (2021).","journal-title":"J. Endocr. Soc."},{"key":"3032_CR505","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1042\/BJ20150910","volume":"473","author":"FA Ross","year":"2016","unstructured":"Ross, F. A., Jensen, T. E. & Hardie, D. G. Differential regulation by AMP and ADP of AMPK complexes containing different gamma subunit isoforms. Biochem. J. 473, 189\u2013199 (2016).","journal-title":"Biochem. J."},{"key":"3032_CR506","doi-asserted-by":"publisher","DOI":"10.1038\/npjgenmed.2016.20","volume":"1","author":"D Memon","year":"2016","unstructured":"Memon, D. et al. Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response. NPJ Genom. Med. 1, 16020 (2016).","journal-title":"NPJ Genom. Med."},{"key":"3032_CR507","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.2337\/db15-0239","volume":"64","author":"P Zhang","year":"2015","unstructured":"Zhang, P. et al. Induction of the ChREBPbeta isoform is essential for glucose-stimulated beta-cell proliferation. Diabetes 64, 4158\u20134170 (2015).","journal-title":"Diabetes"},{"key":"3032_CR508","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/08830185.2010.529976","volume":"30","author":"H Kumar","year":"2011","unstructured":"Kumar, H., Kawai, T. & Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16\u201334 (2011).","journal-title":"Int. Rev. Immunol."},{"key":"3032_CR509","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","volume":"9","author":"GP Amarante-Mendes","year":"2018","unstructured":"Amarante-Mendes, G. P. et al. Pattern recognition receptors and the host cell death molecular machinery. Front. Immunol. 9, 2379 (2018).","journal-title":"Front. Immunol."},{"key":"3032_CR510","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.chembiol.2024.06.003","volume":"31","author":"Y Deng","year":"2024","unstructured":"Deng, Y., Zhou, J. & Li, H. B. The physiological and pathological roles of RNA modifications in T cells. Cell Chem. Biol. 31, 1578\u20131592 (2024).","journal-title":"Cell Chem. Biol."},{"key":"3032_CR511","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s12276-020-0407-z","volume":"52","author":"SH Boo","year":"2020","unstructured":"Boo, S. H. & Kim, Y. K. The emerging role of RNA modifications in the regulation of mRNA stability. Exp. Mol. Med. 52, 400\u2013408 (2020).","journal-title":"Exp. Mol. Med."},{"key":"3032_CR512","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01194-6","volume":"19","author":"H Shi","year":"2020","unstructured":"Shi, H., Chai, P., Jia, R. & Fan, X. Novel insight into the regulatory roles of diverse RNA modifications: Re-defining the bridge between transcription and translation. Mol. Cancer 19, 78 (2020).","journal-title":"Mol. Cancer"},{"key":"3032_CR513","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/sj.mt.6300240","volume":"15","author":"M Robbins","year":"2007","unstructured":"Robbins, M. et al. 2\u2019-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15, 1663\u20131669 (2007).","journal-title":"Mol. Ther."},{"key":"3032_CR514","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","volume":"13","author":"AD Judge","year":"2006","unstructured":"Judge, A. D., Bola, G., Lee, A. C. & MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494\u2013505 (2006).","journal-title":"Mol. Ther."},{"key":"3032_CR515","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","volume":"76","author":"YG Chen","year":"2019","unstructured":"Chen, Y. G. et al. N6-methyladenosine modification controls circular RNA immunity. Mol. Cell 76, 96\u2013109.e109 (2019).","journal-title":"Mol. Cell"},{"key":"3032_CR516","doi-asserted-by":"crossref","unstructured":"Tai, J. & Chen, Y. G. Differences in the immunogenicity of engineered circular RNAs. J. Mol. Cell Biol. 15, mjad002 (2023).","DOI":"10.1093\/jmcb\/mjad002"},{"key":"3032_CR517","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ymthe.2021.01.030","volume":"29","author":"SM Moghimi","year":"2021","unstructured":"Moghimi, S. M. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines. Mol. Ther. 29, 898\u2013900 (2021).","journal-title":"Mol. Ther."},{"key":"3032_CR518","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","volume":"23","author":"Y Ju","year":"2023","unstructured":"Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135\u2013136 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"3032_CR519","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"3032_CR520","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","volume":"30","author":"SM Moghimi","year":"2022","unstructured":"Moghimi, S. M. & Simberg, D. Pro-inflammatory concerns with lipid nanoparticles. Mol. Ther. 30, 2109\u20132110 (2022).","journal-title":"Mol. Ther."},{"key":"3032_CR521","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"3032_CR522","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154-155","author":"GT Kozma","year":"2020","unstructured":"Kozma, G. T., Shimizu, T., Ishida, T. & Szebeni, J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv. Drug Deliv. Rev. 154-155, 163\u2013175 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3032_CR523","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","volume":"23","author":"DE Ingber","year":"2022","unstructured":"Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet. 23, 467\u2013491 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"3032_CR524","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.tibtech.2020.11.014","volume":"39","author":"N Picollet-D\u2019hahan","year":"2021","unstructured":"Picollet-D\u2019hahan, N., Zuchowska, A., Lemeunier, I. & Le Gac, S. Multiorgan-on-a-chip: a systemic approach to model and decipher inter-organ communication. Trends Biotechnol. 39, 788\u2013810 (2021).","journal-title":"Trends Biotechnol."},{"key":"3032_CR525","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41551-022-00882-6","volume":"6","author":"K Ronaldson-Bouchard","year":"2022","unstructured":"Ronaldson-Bouchard, K. et al. A multi-organ chip with matured tissue niches linked by vascular flow. Nat. Biomed. Eng. 6, 351\u2013371 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"3032_CR526","doi-asserted-by":"crossref","unstructured":"Hong, L. et al. Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma. Hepatology, 83, 57\u201374 (2025).","DOI":"10.1097\/HEP.0000000000001283"},{"key":"3032_CR527","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1021\/acs.biomac.2c00399","volume":"23","author":"C Ge","year":"2022","unstructured":"Ge, C. et al. ROS-responsive selenopolypeptide micelles: preparation, characterization, and controlled drug release. Biomacromolecules 23, 2647\u20132654 (2022).","journal-title":"Biomacromolecules"},{"key":"3032_CR528","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.apsb.2022.09.021","volume":"13","author":"Z Dong","year":"2023","unstructured":"Dong, Z. et al. Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharm. Sin. B 13, 955\u2013966 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"3032_CR529","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jconrel.2016.06.034","volume":"257","author":"D Polyak","year":"2017","unstructured":"Polyak, D. et al. Systemic delivery of siRNA by aminated poly(alpha)glutamate for the treatment of solid tumors. J. Control Release 257, 132\u2013143 (2017).","journal-title":"J. Control Release"},{"key":"3032_CR530","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1021\/acs.nanolett.0c00757","volume":"20","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Dual hypoxia-targeting RNAi nanomedicine for precision cancer therapy. Nano Lett. 20, 4857\u20134863 (2020).","journal-title":"Nano Lett."},{"key":"3032_CR531","doi-asserted-by":"crossref","unstructured":"Esawi, E. et al. Aptamer-aptamer chimera for targeted delivery and ATP-responsive release of doxorubicin into cancer cells. Int. J. Mol. Sci. 22, 12940 (2021).","DOI":"10.3390\/ijms222312940"},{"key":"3032_CR532","first-page":"254","volume":"3","author":"X Gao","year":"2022","unstructured":"Gao, X., Ren, E. & Liu, G. Membrane fusion boosting drug transmembrane delivery. Smart Mater. Med. 3, 254\u2013256 (2022).","journal-title":"Smart Mater. Med."},{"key":"3032_CR533","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202301133","volume":"19","author":"Y Zeng","year":"2023","unstructured":"Zeng, Y. et al. Enhanced liposomal drug delivery via membrane fusion triggered by dimeric coiled-coil peptides. Small 19, e2301133 (2023).","journal-title":"Small"},{"key":"3032_CR534","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202408039","volume":"21","author":"J Hammond","year":"2025","unstructured":"Hammond, J. et al. Membrane fusion-based drug delivery liposomes transiently modify the material properties of synthetic and biological membranes. Small 21, e2408039 (2025).","journal-title":"Small"},{"key":"3032_CR535","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/anie.201509673","volume":"55","author":"L Kong","year":"2016","unstructured":"Kong, L. et al. Temporal control of membrane fusion through photolabile pegylation of liposome membranes. Angew. Chem. Int. Ed. Engl. 55, 1396\u20131400 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"3032_CR536","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2019.08.021","volume":"311-312","author":"Z Zheng","year":"2019","unstructured":"Zheng, Z. et al. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J. Control Release 311-312, 43\u201349 (2019).","journal-title":"J. Control Release"},{"key":"3032_CR537","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1039\/C9CC07491K","volume":"55","author":"F He","year":"2019","unstructured":"He, F. et al. Probing exosome internalization pathways through confocal microscopy imaging. Chem. Commun. 55, 14015\u201314018 (2019).","journal-title":"Chem. Commun."},{"key":"3032_CR538","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1021\/acsnano.9b10033","volume":"14","author":"BS Joshi","year":"2020","unstructured":"Joshi, B. S., de Beer, M. A., Giepmans, B. N. G. & Zuhorn, I. S. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano 14, 4444\u20134455 (2020).","journal-title":"ACS Nano"},{"key":"3032_CR539","doi-asserted-by":"publisher","first-page":"D1097","DOI":"10.1093\/nar\/gkad831","volume":"52","author":"L Shen","year":"2024","unstructured":"Shen, L. et al. ADCdb: the database of antibody-drug conjugates. Nucleic Acids Res. 52, D1097\u2013D1109 (2024).","journal-title":"Nucleic Acids Res."},{"key":"3032_CR540","first-page":"205","volume":"434","author":"C Zheng","year":"2008","unstructured":"Zheng, C. & Baum, B. J. Evaluation of promoters for use in tissue-specific gene delivery. Methods Mol. Biol. 434, 205\u2013219 (2008).","journal-title":"Methods Mol. Biol."},{"key":"3032_CR541","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.64","volume":"2","author":"AL Askou","year":"2015","unstructured":"Askou, A. L. et al. Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors. Mol. Ther. Methods Clin. Dev. 2, 14064 (2015).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3032_CR542","doi-asserted-by":"publisher","first-page":"108361","DOI":"10.1016\/j.celrep.2020.108361","volume":"33","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. isoTarget: a genetic method for analyzing the functional diversity of splicing isoforms in vivo. Cell Rep. 33, 108361 (2020).","journal-title":"Cell Rep."},{"key":"3032_CR543","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/S0140-6736(22)02040-2","volume":"400","author":"JP Cerdena","year":"2022","unstructured":"Cerdena, J. P., Grubbs, V. & Non, A. L. Racialising genetic risk: assumptions, realities, and recommendations. Lancet 400, 2147\u20132154 (2022).","journal-title":"Lancet"},{"key":"3032_CR544","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMms2029562","volume":"384","author":"LN Borrell","year":"2021","unstructured":"Borrell, L. N. et al. Race and genetic ancestry in medicine - a time for reckoning with racism. N. Engl. J. Med. 384, 474\u2013480 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3032_CR545","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41586-024-08462-1","volume":"638","author":"JC Means","year":"2025","unstructured":"Means, J. C. et al. Rapid and scalable personalized ASO screening in patient-derived organoids. Nature 638, 237\u2013243 (2025).","journal-title":"Nature"},{"key":"3032_CR546","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11481-025-10227-0","volume":"20","author":"S Mostafa-Tehrani","year":"2025","unstructured":"Mostafa-Tehrani, S. et al. The dopaminergic and anti-neuroinflammatory properties of functionalized nanoliposomes containing levodopa and ibuprofen and conjugated with anti-alpha-synuclein aptamer. J. Neuroimmune Pharmacol. 20, 66 (2025).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"3032_CR547","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2024.214081","volume":"166","author":"AM Gharehbaba","year":"2025","unstructured":"Gharehbaba, A. M. et al. Synergistic pH-responsive MUC-1 aptamer-conjugated Ag\/MSN Janus nanoparticles for targeted chemotherapy, photothermal therapy, and gene therapy in breast cancer. Biomater. Adv. 166, 214081 (2025).","journal-title":"Biomater. Adv."},{"key":"3032_CR548","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.xphs.2024.04.021","volume":"113","author":"BP Vinjamuri","year":"2024","unstructured":"Vinjamuri, B. P., Pan, J. & Peng, P. A review on commercial oligonucleotide drug products. J. Pharm. Sci. 113, 1749\u20131768 (2024).","journal-title":"J. Pharm. Sci."},{"key":"3032_CR549","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1124\/molpharm.124.000895","volume":"106","author":"GM Traber","year":"2024","unstructured":"Traber, G. M. & Yu, A. M. The growing class of novel RNAi therapeutics. Mol. Pharm. 106, 13\u201320 (2024).","journal-title":"Mol. Pharm."},{"key":"3032_CR550","doi-asserted-by":"publisher","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","volume":"189","author":"MM Zhang","year":"2021","unstructured":"Zhang, M. M. et al. The growth of siRNA-based therapeutics: updated clinical studies. Biochem. Pharm. 189, 114432 (2021).","journal-title":"Biochem. Pharm."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03032-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:04:04Z","timestamp":1790244244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03032-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":550,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-03032-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"409"}}